WO2010084661A1 - Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound - Google Patents
Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound Download PDFInfo
- Publication number
- WO2010084661A1 WO2010084661A1 PCT/JP2009/069512 JP2009069512W WO2010084661A1 WO 2010084661 A1 WO2010084661 A1 WO 2010084661A1 JP 2009069512 W JP2009069512 W JP 2009069512W WO 2010084661 A1 WO2010084661 A1 WO 2010084661A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isothiocyanate
- food
- isothiocyanates
- insulin
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention has an action to promote the production and release of calcitonin gene-related peptide (CGRP) and an action to promote the secretion of insulin-like growth factor-1 (IGF-1), and various diseases such as hypertension, obesity and other lifestyle-related diseases, and cognition
- CGRP calcitonin gene-related peptide
- IGF-1 insulin-like growth factor-1
- the present invention relates to isothiocyanates-containing compositions, foods, food materials, medicines, and cosmetics for the purpose of prevention of diseases and depression, improvement of QOL, and beauty.
- CGRP Calcitonin gene related peptide
- CGRP suppresses vasodilation, osteoblast proliferation, osteoclast activation, appetite suppression, and HF k B activation, thereby suppressing TNF- ⁇ production and cancer cell apoptosis.
- CGRP vascular endothelial cells
- production of prostaglandins such as NO and PGI 2 is enhanced, but these substances exert a TNF- ⁇ production inhibitory action in addition to the blood flow increasing action .
- CGRP is known to exert an important effect on the circulatory system, including systemic vasodilation, positive chronotropism and inotropic activity, extracorporeal excretion of NaCl, coronary vasodilation, and renal blood. It has a flow increase effect etc.
- IGF-1 Insulin-like growth factor-1
- IGF-1 is a peptide hormone with a molecular weight of about 7500, which has a structure and action very similar to insulin (see, for example, Non-Patent Document 5).
- IGF-1 is known to actively maintain cells in a healthy state, such as promoting cell differentiation and promoting cell growth (see, for example, Non-Patent Documents 6, 7 and 8).
- the object of the present invention is to provide a composition, food, food material, medicine and cosmetics exhibiting CGRP and IGF-1 secretion promoting action for the purpose of preventing various diseases mentioned above or improving QOL and beauty. is there.
- isothiocyanates and at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acid, cocoa polyphenols, and hachicho-miso Contained in combination it is characterized in that it exhibits a production and release promoting action of calcitonin gene-related peptide (CGRP) or an insulin-like growth factor-1 (IGF-1) secretion promoting action.
- CGRP calcitonin gene-related peptide
- IGF-1 insulin-like growth factor-1
- isothiocyanates and isoflavones isothiocyanates and isoflavones, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and Haccho miso from the group It is characterized in that it contains at least one selected in combination and exhibits a production and release promoting action of calcitonin gene-related peptide (CGRP) or an insulin-like growth factor-1 (IGF-1) secretion promoting action.
- CGRP calcitonin gene-related peptide
- IGF-1 insulin-like growth factor-1
- the present invention contains isothiocyanates and at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acid, cocoa polyphenols, and haccho miso to produce calcitonin gene related peptide (CGRP) And, since it has been made to exhibit a release promoting action and a secretion promoting action of insulin-like growth factor-1 (IGF-1), effects such as prevention of various diseases, improvement of QOL, and beauty can be exhibited.
- IGF-1 insulin-like growth factor-1
- the composition of the present invention is a combination of isothiocyanates with at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acids, cocoa polyphenols, and haccho miso. And each of these components as an essential component.
- the essential component refers to an optional component, and refers to a component which is necessarily contained in the constitution, and is not subject to quantitative restriction.
- the isothiocyanates used in the present invention are 4-methylsulfinylbutyl isothiocyanate, 5-methylsulfinylpentyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate, 7-methylsulfinylheptyl isothiocyanate, 8-methylsulfinyloctyl isothiocyanate, Allyl isothiocyanate, secondary butyl isothiocyanate, 3-butenyl isothiocyanate, 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 5-methyl thiopentyl isothiocyanate, 6-methyl thiohexyl isothiocyanate, 7-methyl thioheptyl isothiocyanate , 8-Methylthiooctyl isothiocyanate, ⁇ -phenethyl isothiocyanate, benzyl
- the isothiocyanates that can be used in the present invention are not limited to the above compounds, and all isothiocyanates can be used as a raw material.
- the above-mentioned isothiocyanates are also effective in chemically synthesized ones, and the effect is not different depending on the synthesis method and the source material, and they do not affect the present invention at all.
- the chemical synthesis of isothiocyanates is specifically described as follows. In principle, it follows the method of Kiaer et al. (Kiaer et al. Acta Chem. Scand, 11, 1298, 1957).
- isothiocyanates can be obtained from cruciferous plants mainly from natural resources.
- the method includes grinding or grating treatment, extraction treatment with a solvent, and drying treatment singly or in combination, the method is not limited at all in the present invention.
- the raw materials containing the above-mentioned isothiocyanates include the following.
- Batissidae (Bataceae), Brassicaceae (Brassicaceae), Breschnadidae (Bretschneideraceae), Citrusaceae (Capparaceae), Papaya (Caricaceae), Euphorbiaceae (Euphorbiaceae), Gyrostemonidae (Gyrostemonaceae), Limnantes ( Limnanthaceae), Wasabinaceae (Moringaceae), Pentadipiprandaceae (Pentadiplandraceae), Phytolaccidae (Phytolaccaceae), Tobellanaceae (Pittosporaceae), Prunellanaceae (Resedaceae), Salvadoriaceae (Salvadoraceae), Touariaceae (Tovar) plants of the family Luceidae (Tropaeolaceae), for example, Batis maritima (Japanese name unknown), wasabi (Wasabia), Bat
- Incana Japanese name unknown
- Shinobumokusou Reseda alba
- Salvadora persica Japanese name unknown
- Tovaria pendula Japanese name unknown
- Kumquat deer Kumquat deer
- the isothiocyanates which can be used in the present invention are not limited to those obtained from the above-mentioned plant species, and all natural resources containing isothiocyanates can be used as a raw material.
- the origin of isoflavones used in the present invention is not particularly limited, and examples thereof include soybean seeds, soya root and foods using them.
- soybean hypocotyl is advantageous because it contains a large amount of isoflavone. It is also possible to use foods such as natto.
- isoflavones daidzein, genistein, glycitein, soy in, genistin, glycitin, 6 ′ ′-O-malonyl soyin, 6 ′ ′-O-malonylgenistin, 6 ′ ′-O-malonylglycitin, 6 ′ ′-O-acetyl soy
- the above-ment daidzein, genistein
- soy and soy foods soy hypocotyls, extracts of soda rootstock and purified products thereof because high concentrations of isoflavones are used.
- the solvent for extracting isoflavones is not particularly limited, but it is preferable to use water or an alcohol such as ethanol.
- a synthetic adsorbent, ion exchange resin, ultrafiltration or the like it is not particularly limited.
- the extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
- the raspberry ketone used in the present invention is not particularly limited, but it is desirable to use raspberry-derived raspberry ketone from the viewpoint of easy collection and safety.
- the capsiate used in the present invention is not particularly limited, but it is desirable to use the variety "CH-19 sweet" selected and bred from pepper, from the viewpoint of easy collection and safety.
- the above raspberry ketone and capsiate may be used as they are by grinding raspberry or the above-mentioned specific pepper variety as it is, but since raspberry ketone or capsiate having a high concentration is used, the extract or its purified product may be used. It is also possible to use.
- the solvent for extracting raspberry ketone and capsiate is not particularly limited, but it is preferable to use water or an alcohol such as ethanol.
- the extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
- capsiate used in the present invention capsaicin may be used, or peppers of generally grown varieties or extracts thereof may be used. Stimulative, long-term, it is difficult for all people to use on a daily basis. Therefore, it is desirable to use capsiate which is considered to be less irritating.
- gluconic acid used in the present invention is not particularly limited, it is desirable to use gluconic acid derived from honey or royal jelly from the viewpoint of easy intake and safety.
- miso and vinegar may be used.
- the chlorogenic acid used in the present invention is not particularly limited, but it is desirable to use coffee bean-derived chlorogenic acid from the viewpoint of easy collection and safety.
- the above gluconic acid and chlorogenic acid can be used by grinding honey and royal jelly or coffee beans as it is, but using gluconic acid and chlorogenic acid with high concentration, their extracts and their purification It is also possible to use a thing.
- the solvent for extracting gluconic acid and chlorogenic acid is not particularly limited, but it is preferable to use water or an alcohol such as ethanol.
- purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited.
- the extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
- gluconic acid used in the present invention it is also possible to use calcium gluconate, potassium gluconate, copper gluconate, sodium gluconate, magnesium gluconate, manganese gluconate and the like as gluconate.
- the cocoa polyphenols used in the present invention can also be taken from foods that use cocoa, such as chocolate and cocoa.
- cocoa polyphenol in order to use a high concentration cocoa polyphenol, it is also possible to use its extract and its refinement
- the solvent for extracting cocoa polyphenol is not particularly limited, but it is preferable to use water or an alcohol such as ethanol.
- purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited.
- the extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
- Hatcho miso used in the present invention is mainly made in Okazaki City, Aichi Prefecture. The soybean miso is characterized by being aged for 2 years or more.
- an extract of Haccho Miso may be used.
- the solvent to be extracted is not particularly limited, but it is preferable to use water or an alcohol such as ethanol.
- purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited.
- the extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
- composition of the present invention comprises, as essential components, isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol, and at least one of hachicho-miso and the isothiocyanates obtained as described above.
- a mixture of these may be used directly as it is, but generally, a solution or dispersion of these in a suitable liquid carrier or a mixture in a suitable powder carrier is used.
- the content for the above-mentioned isothiocyanates to become an active ingredient is usually preferably in the range of 0.0001 to 0.5% by weight (hereinafter abbreviated as "%") in the liquid form, and it is preferable In the case of 0.001 to 20% in the case of granules, it is preferable that the range of 0.001 to 10% is in the case of granules.
- the content of isoflavone as an active ingredient is generally preferably 0.001 to 0.5% by weight (hereinafter abbreviated as "%") in the liquid preparation, and 0. The range of 01 to 80% is preferable, and in the case of granules, the range of 0.01 to 40% is preferable.
- the content for the raspberry ketone to be an active ingredient is usually preferably in the range of 0.05 to 20% in the solution, and preferably in the range of 0.05 to 100% in the case of powders. In the case of granules, it is preferably in the range of 0.05 to 100%.
- the content for the above-mentioned capsiate to become an active ingredient is usually suitably in the range of 0.0001 to 0.05% in the liquid preparation and in the range of 0.0001 to 5% in the dust preparation. In the case of granules, it is preferable to be in the range of 0.0001 to 5%.
- the content for the above-mentioned gluconic acid to become an active ingredient is usually suitably in the range of 0.05 to 10% in the liquid preparation, and in the range of 0.05 to 20% in the powder preparation In the case of granules, the preferred range is 0.05 to 10%.
- the content for the chlorogenic acid to be an active ingredient is generally preferably in the range of 0.05 to 20% in the liquid preparation and in the range of 0.05 to 10% in the dust In the case of granules, the preferred range is 0.05 to 10%.
- the content for the above-mentioned cocoa polyphenol to become an active ingredient is usually suitably in the range of 0.5 to 20% in the liquid preparation and in the range of 0.5 to 10% in the case of powders.
- the content for the above-mentioned Haccho miso to become an active ingredient is usually suitable in the range of 10 to 100% in the liquid preparation, and preferably in the range of 20 to 50% in the powder preparation, In the case of granules, it is preferable that it is in the range of 20 to 50%.
- isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol, and Haccho miso can be used in combination within the above range.
- the edible composition of the present invention is expected to have the same action and effect as the above-mentioned action and effect seen when administered to humans not only in humans but also in animals such as pets and livestock.
- the dose differs depending on the difference between the organisms to be administered and which one of the various effects described above is to be obtained. It is set appropriately. For example, for an adult, the mixture of the above isoflavones etc.
- compositions of the present invention can be taken alone, but can also be used by being added to various food products or medicines. Specifically, liquid foods such as soft drinks, tea beverages, drinks, alcoholic beverages, solid foods such as fruits, breads, noodles, seasonings, etc., pharmaceuticals such as powders, granules, capsules and tablets Add to quasi-drugs etc.
- the composition of the present invention can also obtain the same effect as taking it orally or applying it by sniffing the isothiocyanate contained or exposing it to volatilized isothiocyanates. . Specifically, it can be used by blending it into an aroma oil, a fragrance, daily necessities for perfume, cosmetics, perfumes, fibers or resins, etc. and volatilizing the components.
- the concentration when exposed to volatilized isothiocyanate, the concentration is not limited, but it is desirable that the concentration is within the range that can be recognized by human being without causing irritation or discomfort. There is no particular relationship between the concentration and the effect.
- Test Example 1 Changes in IGF-1 and CGRP Concentrations in Mice by Administration of Isothiocyanates
- a standard diet was prepared for C57BL / 6 mice (male, 5 mice in each group) of 6-8 weeks divided into 16 groups.
- a test product was administered. After administration for 4 weeks, various organs collected under anesthesia were immersed in 1 N acetic acid solution, homogenized, and centrifuged to measure IGF-1 concentration in the supernatant. Blood was also collected to measure plasma IGF-1 and CGRP concentrations. The concentrations of IGF-1 and CGRP in mouse brain and plasma are shown in Table 1.
- 6-MSITC 6-methylsulfinyl hexyl isothiocyanate
- the above 16 groups are administered 6-MSITC (MS), isoflavone (IS), 6-MSITC + isoflavone (MS + IS) administered, raspberry ketone (RA) administered, 6-MSITC Raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + gluconic acid (MS + GA) administration group, chlorogenic acid (CA) administration group 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) administration group, 6-MSITC + Haccho miso (MS + HM) administration group Any of non-administration group (standard diet
- each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day.
- the IS administration group 50 mg / kg / day of isoflavone was administered.
- the RA administration group 400 mg / kg / day of raspberry ketone was administered.
- the CE administration group administration of 0.1 mg / kg of capsiate.
- gluconic acid was administered at 1 mg / kg / day.
- chlorogenic acid was administered at 1 mg / kg / day.
- CP administration group 50 mg / kg / day of cocoa polyphenol was administered.
- Haccho Miso was administered at 600 mg / kg / day.
- mice The effect of improving learning function by isothiocyanates For the mice divided into 16 groups (5 mice in each group), in addition to the standard diet for 4 weeks a test product is administered, and then the Morris water maze test is carried out for 5 days And assessed the impact on the learning function.
- the above 16 groups are administered 6-MSITC (MS), isoflavone (IS), 6-MSITC + isoflavone (MS + IS) administered, raspberry ketone (RA) administered, 6-MSITC Raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + gluconic acid (MS + GA) administration group, chlorogenic acid (CA) administration group 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) administration group, 6-MSITC + Haccho miso (MS + HM) administration group Any of the non-administration group (standard diet only, control group) Or to belong.
- each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day.
- the IS administration group 50 mg / kg / day of isoflavone was administered.
- the RA administration group 400 mg / kg / day of raspberry ketone was administered.
- the CE administration group 0.1 mg / kg of capsiate was administered.
- the GA administration group gluconic acid was administered at 1 mg / kg / day.
- chlorogenic acid was administered at 1 mg / kg / day.
- cocoa polyphenol 50 mg / kg / day was administered.
- Haccho Miso was administered at 600 mg / kg / day.
- Test Example 3 Test of nerve regeneration effect in mouse brain by 6-MSITC administration After Example 2, the brains of mice used in the experiment were collected, and the influence on nerve regeneration was evaluated. At that time, newborn neurons were detected by using 5-bromo-2-deoxyuridine (Brdu) and Brdu antibodies. Histological evaluation was performed by measuring left and right hippocampal neuronal layer length and neuronal cell number and calculating the number per unit length (mm). As a result, the number of neoplastic cells was significantly increased in the MS administration group as compared to the control group. In addition, in the group administered in combination with MS and other test substances, the tendency to increase was more remarkable.
- Prdu 5-bromo-2-deoxyuridine
- Example 4 Evaluation of antidepressant action by 6-MSITC administration As in Example 2, divided into 16 groups, the effect on the antidepressant action in mice receiving the standard diet and each test sample was examined by tail suspension test . Male mice weighing 20-25 g and 8 weeks old were used. The tail of the mouse was pinched and hung upside down with a wooden clip fixed at a height of 35 cm from the floor on a stand 60 cm high. The mouse is active at first, but gives up gradually to move. The antidepressant effect of the administered ingredients was evaluated as shortening of the non-moving time (inactive time) within 6 minutes after the start of suspension. As a result, in the MS administration group, the inactive time was significantly reduced by 30% as compared with the control group.
- Test Example 5 Test of action to promote calcitonin gene related peptide production by 6-MSITC in ovariectomized rats and effect on osteoporosis 80 SD female rats (5 rats per group, divided into 17 groups) Twenty groups of 21 groups were given an ovariectomized rat on day 10 after excision and a standard diet [Ca-deficient diet (Ca: 0.004%, P: 0.3%)] etc. I kept it for 28 days. Thereafter, they were fasted overnight (18 hours), and rats in all groups were sacrificed and femurs were removed therefrom.
- the 16 groups from which the ovaries were removed were, for example, the 6-MSITC (MS) administration group, the isoflavone (IS) administration group, 6-MSITC + isoflavone (MS + IS IS Administration group, raspberry ketone (RA) administration group, 6-MSITC + raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + glucone Acid (MS + GA) administration group, chlorogenic acid (CA) administration group, 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) Administration group, 6-MSITC + Haccho miso (MS + HM) administration , It belongs to one of the non-administered group (standard diet only.
- Control group That is, each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day.
- IS administration group 50 mg / kg / day of isoflavone was administered.
- RA administration group raspberry ketone 400 mg / kg / day was administered.
- CE administration group 0.1 mg / kg of capsiate was administered.
- GA administration group gluconic acid was administered at 1 mg / kg / day.
- CA administration group chlorogenic acid 1 mg / kg / day was administered.
- CP administration group 50 mg / kg / day of cocoa polyphenol was administered.
- HM Haccho Miso was administered at 600 mg / kg / day. Furthermore, the combination of MS + IS, MS + RA, MS + CE, MS + GA, MS + CA, MS + CP, and MS + HM was performed using these combinations. Then, based on the femur removed from the 17 groups described above, that is, the normal group (without ovariectomy) and the control group (ovariectomy) and 15 test groups (administration of ovariectomy + 6-MSITC etc.) The weight was measured and the volume was measured by a pycnometer to calculate bone density. In addition, measurement of calcitonin gene related peptide concentration (CGRP) in bone tissue was also performed. These results are shown together in Table 3 below.
- CGRP calcitonin gene related peptide concentration
- 6-MSITC intake of 6-MSITC has an effect on hypertension since it promotes production and release of calcitonin gene-related peptide. Furthermore, it has been confirmed that the action is enhanced by the combination of 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol and Haccho miso.
- the animals were fed with a feed adjusted to have an intake of capsiate (CE) of 1 mg / kg body weight / day.
- CE capsiate
- the animals were fed with a feed adjusted to have an intake of gluconic acid (GA) of 4 mg / kg body weight / day.
- the animals were fed with a feed adjusted to have an intake of chlorogenic acid (CA) of 3 mg / kg body weight / day.
- CA chlorogenic acid
- the animals were fed with a feed adjusted to have an intake of cocoa polyphenol (CP) of 200 mg / kg body weight / day.
- CP cocoa polyphenol
- the animals were reared with a feed adjusted to have an intake of 600 mg / kg body weight / day of Haccho Miso (HM).
- At least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and haccho miso and 6-MSITC are simultaneously measured as a result of measuring the amount of calcitonin gene-related peptide and insulin-like growth factor in hair follicles. It was found that the given group was significantly more than the other groups.
- gluconic acid 100 mg was ingested daily by administration of a tablet containing gluconic acid (GA).
- 100 mg of chlorogenic acid was ingested daily by administration of a tablet containing chlorogenic acid (CA).
- CA chlorogenic acid
- CP cocoa polyphenol
- HM Hachidamei
- Groups 3, 5, 7, 9, 11, 13, 15 were also ingested with these combinations as shown in Table 5.
- Group 16 was ingested a simulated tablet. This was done for six months.
- the number of hair loss collected during the above test was measured to evaluate the hair loss improving effect.
- the measurement method of the above-mentioned hair loss performed four days continuous hair washing, collected the hair loss of the last three days with the fine nonwoven fabric of mesh, counted the number, and was performed. And the judgment of the said evaluation was shown as follows from the change of the number of hair loss in each time with respect to sampling before. +++: The number of hair loss has been reduced by 30 or more, and a remarkable effect was observed. ++: The number of hair loss has been reduced by more than 20, and a considerable effect was observed. +: The number of hair loss was reduced by 10 or more, and a slight effect was observed.
- ⁇ Decrease or decrease in the number of hair loss was less than 10, and almost no effect was observed. From the results in Table 5 above, when 6-MSITC is ingested alone or in combination with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and Haccho miso together with 6-MSITC, a simulated tablet is obtained. Hair loss was improved compared to the group who received Also, in the group in which 6-MSITC and isoflavone or royal jelly were simultaneously ingested, a remarkable improvement effect on hair loss was observed.
- Test of hair growth effect on humans by applying lotion containing isothiocyanates The subject was a volunteer male (30 to 50 years old) having hair loss and thin hair trouble, and was divided into a total of 9 groups of 5 persons. .
- groups 1 to 8 1 ml of a lotion containing 0.01% of 6-MSITC is applied to the scalp once a day, and in group 2, isoflavone is taken as a 50 mg tablet daily, and in group 3 raspberry ketone is daily It was ingested in a 600 mg tablet.
- capsiate was ingested in 2 mg tablets per day, and in group 5 gluconic acid was ingested in 100 mg tablets per day.
- group 6 chlorogenic acid was ingested in 100 mg tablets per day, and in group 7, cocoa polyphenol was ingested in 600 mg tablets per day.
- group 8 Hachcho miso was ingested in a daily dose of 5000 mg tablets, and group 9 was similarly applied with a lotion containing no 6-MSITC as a control group, and ingested simulated tablets. This was done for six months. Next, the number of hair loss collected during the above test (before the start of application of the lotion, after 3 months of application and after 6 months of application) was measured to evaluate the hair loss improving effect.
- the measurement method of the above-mentioned hair loss performed four days continuous hair washing, collected the hair loss of the last three days with the fine nonwoven fabric of mesh, counted the number, and was performed. And judgment of the above-mentioned evaluation was displayed as follows from change of the number of hair loss in each time to before the start of application of a lotion. +++: The number of hair loss decreased by 30 or more, and a remarkable effect was recognized. ++: The number of hair loss decreased by 20 or more, and a considerable effect was recognized. +: The number of hair loss decreased by 10 or more, and a slight effect was recognized. ⁇ : The decrease in the number of hair loss is less than or increased by 10, and it can not be said to be effective. The results are shown in Table 7 below.
- the composition of the present invention comprises, as essential components, at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and hacho-miso and 6-MSITC, and is derived from insulin-like growth factor-I.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided is a composition having an activity to promote the production and release of a calcitonin gene-related peptide (CGRP) and an activity to promote the secretion of insulin-like growth factor-1 (IGF-1). The composition can contribute to the prevention of various diseases, the improvement in QRL, the increase in beauty and the like.
The composition comprises a combination of an isothiocyanate compound and at least one substance selected from a group consisting of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol and Haccho miso (a kind of fermented soybean paste).
Description
本発明はカルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用、ならびにインスリン様成長因子−1(IGF−1)の分泌促進作用を呈し、各種疾患、例えば高血圧、肥満などの生活習慣病、認知症やうつ病などの予防、QOLの向上、美容を目的とするイソチオシアネート類含有組成物、食品、食品素材、医薬品、および化粧品に関する。
The present invention has an action to promote the production and release of calcitonin gene-related peptide (CGRP) and an action to promote the secretion of insulin-like growth factor-1 (IGF-1), and various diseases such as hypertension, obesity and other lifestyle-related diseases, and cognition The present invention relates to isothiocyanates-containing compositions, foods, food materials, medicines, and cosmetics for the purpose of prevention of diseases and depression, improvement of QOL, and beauty.
現代社会において、生活習慣や食生活の変化、社会的なストレスの増加により、各種疾患が問題となっている。例えば、高血圧、肥満などの生活習慣や、認知症、うつ病などが挙げられる。これらは、医療費増加や少子高齢化の問題もあり、副作用のある医薬品での治療にたよるのではなく、生活習慣や食生活における予防、再発防止が望まれる。
カルシトニン遺伝子関連ペプチド(CGRP)は、ホルモンであるカルシトニンと構造が非常に類似した37個のアミノ酸からなるペプチドで、この遺伝子はカルシトニン遺伝子と同じ遺伝子上にあり、そのオルタナティブ・スプライシングにより生成される。
CGRPは、血管拡張作用、骨芽細胞の増殖、また破骨細胞の活性化抑制、食欲の抑制、さらにHFkBの活性化を抑制して、TNF−αの産生抑制や癌細胞のアポトーシスを促進する。また、CGRP血管内皮細胞に作用することにより、NOや、PGI2などのプロスタグランジンの産生が亢進するが、これらの物質は、血流増加作用に加えてTNF−α産生抑制作用を発揮する。
さらに、CGRPは、循環器系にも重要な作用をおよぼすことが知られており、全身の血管拡張作用、陽性変時および変力作用、NaClの体外排泄作用、冠血管拡張作用、および腎血流増加作用などを有している。
さらにCGRPは肝臓ならびにすべての組織においてインスリン様成長因子の産生を促進することが明らかになっている(以上非特許文献1から4参照)。
インスリン様成長因子−1(insulin−like growth factor−1)(IGF−1)はインスリンに非常に似た構造および作用を持つ分子量約7500のペプチドホルモンである(例えば、非特許文献5参照)。IGF−1は細胞の分化を促し、細胞の増殖を助ける等、積極的に細胞を健康な状態に維持することが知られている(例えば、非特許文献6、7、8参照。)
近年、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用を有する可食性組成物として、カプサイシンによるカルシトニン遺伝子関連ペプチドの放出促進作用と、イソフラボンによるカルシトニン遺伝子関連ペプチドの産生促進作用を組み合わせた胃粘膜障害、生活習慣病、肥満、悪性腫瘍および骨粗鬆症の予防および治療用、臓器移植拒絶反応軽減用、感染等の侵襲要因に対する生体侵襲反応に伴う臓器障害の予防と軽減用、さらには育毛用の、可食性組成物が提案されている(特許文献1参照)。
アブラナ科植物に多く含まれることで知られているイソチオシアネート類は、その生理活性が数例報告されている。しかし、イソチオシアネート類がCGRPおよびIGF−1の分泌を促進させる等の言及はなく、またアブラナ科植物やイソチオシアネート類とCGRP、IGF−1との関係を示唆する記載も認められない。
IGF−1分泌促進作用のある食品成分、または数種類の食品成分によるIGF−1分泌促進作用については上記のように報告されている。しかしながら、これらの成分は刺激を有する成分である場合もあり、また単一の成分を日常的に多量に摂取することは難しい。栄養学的な見地からも、できるだけ多数の食品、または食品成分を摂取することが望まれる。
岡嶋研二著「生体浸襲と疾患−重症敗血症から生活習慣病まで」現代医療社、2003年 Harada N.et al.Am.J.Physiol.Gastrointest.Liver.Physiol.2003 Jul 31 Vignery A.et al.Bone 1996 Vol.18 No.4 331−335 Philpott MP.et al.J.Invest.Dermatol.1994 Vol.102 No.6 857−861 グッドマン・ギルマン薬理書[下]薬物治療の基礎と臨床−第10版−;第61章インスリン、経口血糖降下薬と脾臓内分泌の薬理学2003、p2144監訳:高折 修二、福田 英臣、赤池 昭紀 東京廣川書店発行 Corn K J.et al.J.Biol.Chem.1996 Vol.271 No.46 28853−28860 Braham C.et al.Dermatology 2002 Vol.20 No.4 325−329 Roubenoff R.et al.Am.J.Med.2003 Vol.115 No.6 501−502 特開2005−68129公報
In modern society, various diseases have become a problem due to changes in lifestyle and eating habits and increased social stress. For example, lifestyles such as high blood pressure and obesity, dementia, depression and the like can be mentioned. These are problems of increased medical expenses and declining birthrate and aging, and it is desirable not to rely on treatment with drugs that have side effects, but to prevent lifestyle habits and eating habits and prevent recurrence.
Calcitonin gene related peptide (CGRP) is a peptide consisting of 37 amino acids whose structure is very similar to that of calcitonin which is a hormone, and this gene is on the same gene as calcitonin gene and is produced by its alternative splicing.
CGRP suppresses vasodilation, osteoblast proliferation, osteoclast activation, appetite suppression, and HF k B activation, thereby suppressing TNF-α production and cancer cell apoptosis. Facilitate. In addition, by acting on CGRP vascular endothelial cells, production of prostaglandins such as NO and PGI 2 is enhanced, but these substances exert a TNF-α production inhibitory action in addition to the blood flow increasing action .
Furthermore, CGRP is known to exert an important effect on the circulatory system, including systemic vasodilation, positive chronotropism and inotropic activity, extracorporeal excretion of NaCl, coronary vasodilation, and renal blood. It has a flow increase effect etc.
Furthermore, CGRP has been shown to promote the production of insulin-like growth factor in liver as well as in all tissues (see Non-patent Documents 1 to 4 above).
Insulin-like growth factor-1 (IGF-1) is a peptide hormone with a molecular weight of about 7500, which has a structure and action very similar to insulin (see, for example, Non-Patent Document 5). IGF-1 is known to actively maintain cells in a healthy state, such as promoting cell differentiation and promoting cell growth (see, for example, Non-Patent Documents 6, 7 and 8).
In recent years, as an edible composition having a calcitonin gene related peptide (CGRP) production and release promoting action, the gastric mucosa combining capsaicin release promoting action of calcitonin gene related peptide and isoflavone promoting production of calcitonin gene related peptide For the prevention and treatment of disorders, lifestyle-related diseases, obesity, malignancy and osteoporosis, for the reduction of organ transplant rejection, for the prevention and alleviation of organ damage associated with the body invasive reaction to invasive factors such as infection, and for hair growth, Edible compositions have been proposed (see Patent Document 1).
Isothiocyanates, which are known to be abundant in cruciferous plants, have been reported in several cases for their physiological activity. However, there is no mention that isothiocyanates promote the secretion of CGRP and IGF-1, etc. There is also no description suggesting a relationship between crucifers and isothiocyanates and CGRP or IGF-1.
The IGF-1 secretion promoting action of a food ingredient having an IGF-1 secretion promoting action, or several kinds of food ingredients has been reported as described above. However, these ingredients may be irritating ingredients, and it is difficult to take large amounts of single ingredients on a daily basis. From a nutritional point of view, it is desirable to consume as much food or food ingredients as possible.
Okaji Kenji, "Bio-invasion and diseases-from severe sepsis to lifestyle-related diseases," Hyundai Medical, 2003 Harada N. et al. Am. J. Physiol. Gastrointest. Liver. Physiol. 2003 Jul 31 Vignery A. et al. Bone 1996 Vol. 18 No. 4 331-335 Philpott MP. et al. J. Invest. Dermatol. 1994 Vol. 102 No. 6 857-861 Goodman-Gillman Pharmacology Book [Bottom] Basics and Clinical Practice of Drug Treatment-10th Edition-Chapter 61. Insulin, Oral Hypoglycemic Drugs and Pharmacology of Splenic Endocrine 2003, p 2144 監: Shuji Takanori, Hidetoshi Fukuda, Akinori Akaike Tokyo Published by Kamogawa Bookstore Corn K J. et al. J. Biol. Chem. 1996 Vol. 271 No. 46 28853-28860 Braham C. et al. Dermatology 2002 Vol. 20 No. 4 325-329 Roubenoff R. et al. Am. J. Med. 2003 Vol. 115 No. 6 501-502 JP 2005-68129 A
カルシトニン遺伝子関連ペプチド(CGRP)は、ホルモンであるカルシトニンと構造が非常に類似した37個のアミノ酸からなるペプチドで、この遺伝子はカルシトニン遺伝子と同じ遺伝子上にあり、そのオルタナティブ・スプライシングにより生成される。
CGRPは、血管拡張作用、骨芽細胞の増殖、また破骨細胞の活性化抑制、食欲の抑制、さらにHFkBの活性化を抑制して、TNF−αの産生抑制や癌細胞のアポトーシスを促進する。また、CGRP血管内皮細胞に作用することにより、NOや、PGI2などのプロスタグランジンの産生が亢進するが、これらの物質は、血流増加作用に加えてTNF−α産生抑制作用を発揮する。
さらに、CGRPは、循環器系にも重要な作用をおよぼすことが知られており、全身の血管拡張作用、陽性変時および変力作用、NaClの体外排泄作用、冠血管拡張作用、および腎血流増加作用などを有している。
さらにCGRPは肝臓ならびにすべての組織においてインスリン様成長因子の産生を促進することが明らかになっている(以上非特許文献1から4参照)。
インスリン様成長因子−1(insulin−like growth factor−1)(IGF−1)はインスリンに非常に似た構造および作用を持つ分子量約7500のペプチドホルモンである(例えば、非特許文献5参照)。IGF−1は細胞の分化を促し、細胞の増殖を助ける等、積極的に細胞を健康な状態に維持することが知られている(例えば、非特許文献6、7、8参照。)
近年、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用を有する可食性組成物として、カプサイシンによるカルシトニン遺伝子関連ペプチドの放出促進作用と、イソフラボンによるカルシトニン遺伝子関連ペプチドの産生促進作用を組み合わせた胃粘膜障害、生活習慣病、肥満、悪性腫瘍および骨粗鬆症の予防および治療用、臓器移植拒絶反応軽減用、感染等の侵襲要因に対する生体侵襲反応に伴う臓器障害の予防と軽減用、さらには育毛用の、可食性組成物が提案されている(特許文献1参照)。
アブラナ科植物に多く含まれることで知られているイソチオシアネート類は、その生理活性が数例報告されている。しかし、イソチオシアネート類がCGRPおよびIGF−1の分泌を促進させる等の言及はなく、またアブラナ科植物やイソチオシアネート類とCGRP、IGF−1との関係を示唆する記載も認められない。
IGF−1分泌促進作用のある食品成分、または数種類の食品成分によるIGF−1分泌促進作用については上記のように報告されている。しかしながら、これらの成分は刺激を有する成分である場合もあり、また単一の成分を日常的に多量に摂取することは難しい。栄養学的な見地からも、できるだけ多数の食品、または食品成分を摂取することが望まれる。
岡嶋研二著「生体浸襲と疾患−重症敗血症から生活習慣病まで」現代医療社、2003年 Harada N.et al.Am.J.Physiol.Gastrointest.Liver.Physiol.2003 Jul 31 Vignery A.et al.Bone 1996 Vol.18 No.4 331−335 Philpott MP.et al.J.Invest.Dermatol.1994 Vol.102 No.6 857−861 グッドマン・ギルマン薬理書[下]薬物治療の基礎と臨床−第10版−;第61章インスリン、経口血糖降下薬と脾臓内分泌の薬理学2003、p2144監訳:高折 修二、福田 英臣、赤池 昭紀 東京廣川書店発行 Corn K J.et al.J.Biol.Chem.1996 Vol.271 No.46 28853−28860 Braham C.et al.Dermatology 2002 Vol.20 No.4 325−329 Roubenoff R.et al.Am.J.Med.2003 Vol.115 No.6 501−502
Calcitonin gene related peptide (CGRP) is a peptide consisting of 37 amino acids whose structure is very similar to that of calcitonin which is a hormone, and this gene is on the same gene as calcitonin gene and is produced by its alternative splicing.
CGRP suppresses vasodilation, osteoblast proliferation, osteoclast activation, appetite suppression, and HF k B activation, thereby suppressing TNF-α production and cancer cell apoptosis. Facilitate. In addition, by acting on CGRP vascular endothelial cells, production of prostaglandins such as NO and PGI 2 is enhanced, but these substances exert a TNF-α production inhibitory action in addition to the blood flow increasing action .
Furthermore, CGRP is known to exert an important effect on the circulatory system, including systemic vasodilation, positive chronotropism and inotropic activity, extracorporeal excretion of NaCl, coronary vasodilation, and renal blood. It has a flow increase effect etc.
Furthermore, CGRP has been shown to promote the production of insulin-like growth factor in liver as well as in all tissues (see Non-patent Documents 1 to 4 above).
Insulin-like growth factor-1 (IGF-1) is a peptide hormone with a molecular weight of about 7500, which has a structure and action very similar to insulin (see, for example, Non-Patent Document 5). IGF-1 is known to actively maintain cells in a healthy state, such as promoting cell differentiation and promoting cell growth (see, for example, Non-Patent Documents 6, 7 and 8).
In recent years, as an edible composition having a calcitonin gene related peptide (CGRP) production and release promoting action, the gastric mucosa combining capsaicin release promoting action of calcitonin gene related peptide and isoflavone promoting production of calcitonin gene related peptide For the prevention and treatment of disorders, lifestyle-related diseases, obesity, malignancy and osteoporosis, for the reduction of organ transplant rejection, for the prevention and alleviation of organ damage associated with the body invasive reaction to invasive factors such as infection, and for hair growth, Edible compositions have been proposed (see Patent Document 1).
Isothiocyanates, which are known to be abundant in cruciferous plants, have been reported in several cases for their physiological activity. However, there is no mention that isothiocyanates promote the secretion of CGRP and IGF-1, etc. There is also no description suggesting a relationship between crucifers and isothiocyanates and CGRP or IGF-1.
The IGF-1 secretion promoting action of a food ingredient having an IGF-1 secretion promoting action, or several kinds of food ingredients has been reported as described above. However, these ingredients may be irritating ingredients, and it is difficult to take large amounts of single ingredients on a daily basis. From a nutritional point of view, it is desirable to consume as much food or food ingredients as possible.
Okaji Kenji, "Bio-invasion and diseases-from severe sepsis to lifestyle-related diseases," Hyundai Medical, 2003 Harada N. et al. Am. J. Physiol. Gastrointest. Liver. Physiol. 2003 Jul 31 Vignery A. et al. Bone 1996 Vol. 18 No. 4 331-335 Philpott MP. et al. J. Invest. Dermatol. 1994 Vol. 102 No. 6 857-861 Goodman-Gillman Pharmacology Book [Bottom] Basics and Clinical Practice of Drug Treatment-10th Edition-Chapter 61. Insulin, Oral Hypoglycemic Drugs and Pharmacology of Splenic Endocrine 2003, p 2144 監: Shuji Takanori, Hidetoshi Fukuda, Akinori Akaike Tokyo Published by Kamogawa Bookstore Corn K J. et al. J. Biol. Chem. 1996 Vol. 271 No. 46 28853-28860 Braham C. et al. Dermatology 2002 Vol. 20 No. 4 325-329 Roubenoff R. et al. Am. J. Med. 2003 Vol. 115 No. 6 501-502
そこで本発明の課題は、上述の各種疾患の予防、またはQOLの向上、美容を目的としたCGRPおよびIGF−1分泌促進作用を呈する組成物、食品、食品素材、医薬品および化粧品を提供することにある。
Therefore, the object of the present invention is to provide a composition, food, food material, medicine and cosmetics exhibiting CGRP and IGF-1 secretion promoting action for the purpose of preventing various diseases mentioned above or improving QOL and beauty. is there.
上述の課題を解決するため、本発明の組成物によれば、イソチオシアネート類と、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の群から選択される少なくとも一種とを組み合わせて含有し、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用またはインスリン様成長因子−1(IGF−1)分泌促進作用を呈することを特徴とする。
さらに上述の課題を解決するため、本発明の食品、食品素材、医薬品および化粧品によれば、イソチオシアネート類と、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の群から選択される少なくとも一種とを組み合わせて含有し、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用またはインスリン様成長因子−1(IGF−1)分泌促進作用を呈することを特徴とする。 In order to solve the above-mentioned problems, according to the composition of the present invention, isothiocyanates and at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acid, cocoa polyphenols, and hachicho-miso Contained in combination, it is characterized in that it exhibits a production and release promoting action of calcitonin gene-related peptide (CGRP) or an insulin-like growth factor-1 (IGF-1) secretion promoting action.
In order to solve the above-mentioned problems, according to the food, food material, medicine and cosmetics of the present invention, isothiocyanates and isoflavones, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and Haccho miso from the group It is characterized in that it contains at least one selected in combination and exhibits a production and release promoting action of calcitonin gene-related peptide (CGRP) or an insulin-like growth factor-1 (IGF-1) secretion promoting action.
さらに上述の課題を解決するため、本発明の食品、食品素材、医薬品および化粧品によれば、イソチオシアネート類と、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の群から選択される少なくとも一種とを組み合わせて含有し、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用またはインスリン様成長因子−1(IGF−1)分泌促進作用を呈することを特徴とする。 In order to solve the above-mentioned problems, according to the composition of the present invention, isothiocyanates and at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acid, cocoa polyphenols, and hachicho-miso Contained in combination, it is characterized in that it exhibits a production and release promoting action of calcitonin gene-related peptide (CGRP) or an insulin-like growth factor-1 (IGF-1) secretion promoting action.
In order to solve the above-mentioned problems, according to the food, food material, medicine and cosmetics of the present invention, isothiocyanates and isoflavones, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and Haccho miso from the group It is characterized in that it contains at least one selected in combination and exhibits a production and release promoting action of calcitonin gene-related peptide (CGRP) or an insulin-like growth factor-1 (IGF-1) secretion promoting action.
本発明はイソチオシアネート類と、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の群から選択される少なくとも一種とを組み合わせて含有せしめ、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用ならびにインスリン様成長因子−1(IGF−1)の分泌促進作用を呈するようにしたから、各種疾患の予防、QOLの向上、美容等の効果を奏し得る。
The present invention contains isothiocyanates and at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acid, cocoa polyphenols, and haccho miso to produce calcitonin gene related peptide (CGRP) And, since it has been made to exhibit a release promoting action and a secretion promoting action of insulin-like growth factor-1 (IGF-1), effects such as prevention of various diseases, improvement of QOL, and beauty can be exhibited.
以下、本発明を具体的に詳述する。
本発明の組成物は、先にも述べたように、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌からなる群から選ばれた少なくとも一つと、イソチオシアネート類との組み合わせを特徴とするものであり、これら各成分を必須成分として含有するものである。このような構成によって、カルシトニン遺伝子関連ペプチドの産生および放出が著明に促進され、IGF−1の分泌が促進されるようになる。ここで、必須成分とは、任意成分に対するものであって、構成上必ず含有される成分のことをいい、量的な制約は受けない。
本発明に用いられるイソチオシアネート類は、4−メチルスルフィニルブチルイソチオシアネート、5−メチルスルフィニルペンチルイソチオシアネート、6−メチルスルフィニルヘキシルイソチオシアネート、7−メチルスルフィニルヘプチルイソチオシアネート、8−メチルスルフィニルオクチルイソチオシアネート、アリルイソチオシアネート、第2級ブチルイソチオシアネート、3−ブテニルイソチオシアネート、4−ペンテニルイソチオシアネート、5−ヘキセニルイソチオシアネート、5−メチルチオペンチルイソチオシアネート、6−メチルチオヘキシルイソチオシアネート、7−メチルチオヘプチルイソチオシアネート、8−メチルチオオクチルイソチオシアネート、β−フェネチルイソチオシアネート、ベンジルイソチオシアネート、フェニルイソチオシアネート、およびフェネチルイソチオシアネート等が挙げられ、これらを単独で、あるいは複数種を組み合わせて使用される。ただし、本発明で使用できるイソチオシアネート類は、上記の化合物に限定されるものではなく、イソチオシアネート類全てが原料として使用できる。
上述のイソチオシアネート類は、化学的に合成されたものにおいても有効であり、その合成法、起源物質により効果に違いは無く、本発明には全く影響をおよぼすものではない。
イソチオシアネート類の化学合成法を具体的に説明すると、以下のとおりである。
原理的にはKiaer等の方法にしたがう。(Kiaer etal.Acta Chem.Scand,11,1298,1957年)。出発物質としてω−クロロアルケノールを用い、CH3−SNaと還流してω−メチルチオアルケノールを得、これにSOCl2を作用させてω−クロロアルケノールメチルサルファイドを得る。
次にガブリエル法を用いてアミノ基を導入し、N−(ω−メチルチオアルキル)−フタルイミドを生成し、これらにヒドラジン水化物を加えて還流し、ω−メチルチオアルキルアミンを得る。さらに、Li等の方法(Lietal.J.Org.Chem.,62,4539,1997年)にしたがい、ラウチムジスルフィドを経て得られたω−メチルチオアルキルイソチオシアネートをmCPBAでメチルチオ基を酸化し、ω−メチルスルフィニルアルキルイソチオシアネートを得る。
本発明において、イソチオシアネート類はアブラナ科植物を主として天然資源より得ることができる。また、その方法としては粉砕またはすりおろし処理、溶媒による抽出処理、乾燥処理を単独または組み合わせ処理が挙げられるが、本発明に関して、その方法は一切限定されるものではない。
上述のイソチオシアネート類を含む原料としては以下のようなものが挙げられる。例えば、バティス科(Bataceae)、アブラナ科(Brassicaceae)、ブレッシュネイデラ科(Bretschneideraceae)、フウチョウソウ科(Capparaceae)、パパイア科(Caricaceae)、トウダイグサ科(Euphorbiaceae)、ギロステモン科(Gyrostemonaceae)、リムナンテス科(Limnanthaceae)、ワサビノキ科(Moringaceae)、ペンタディプランドラ科(Pentadiplandraceae)、ヤマゴボウ科(Phytolaccaceae)、トベラ科(Pittosporaceae)、モクセイソウ科(Resedaceae)、サルウァドラ科(Salvadoraceae)、トウァリア科(Tovariaceae)、ノウゼンハレン科(Tropaeolaceae)、の植物、例えば、Batis maritima(和名不詳)、本わさび(Wasabia japonica)、西洋わさび(Armoracia rusticana)、からし(Brassica juncea)、ブロッコリー(Brassica oleracea var.italica)、シロイヌナズナ(Arabidopsis thaliana)、ナズナ(Capsella bursa−pastoris)、クレソン(Nasturtium officinale)、Bretschneidera sinensis(和名不詳)、ケッパー(Capparis spinosa)、パパイア(Carica papaya)、Drypetes roxburghii(別名);Putranjiva roxburghii(和名不詳)、Tersonia brevipes(和名不詳)、Limnanthes douglasii(和名不詳)、ワサビノキ(Moringa oleifera)、Pentadiplandra brazzeana(和名不詳)、ヨウシュヤマゴボウ(Phytolacca americana)、Bursaris spinosa var.incana(和名不詳)、シノブモクセイソウ(Reseda alba)、Salvadora persica(和名不詳)、Tovaria pendula(和名不詳)、キンレンカ(Tropaeolum majus)等が使用できる。ただし、本発明で使用できるイソチオシアネート類は、上記の植物種から得られるものに限定されるものではなく、イソチオシアネート類を含有する全ての天然資源が原料として使用できる。
一方、本発明に用いるイソフラボンの由来は、特に限定されるものではなく、例えば、大豆種子、葛根およびそれらを用いた食品などが挙げられる。なかでも大豆の胚軸にはイソフラボンが多量に含まれるため都合が良い。また、納豆などの食品を用いることも可能である。
上記イソフラボンには、ダイゼイン、ゲニステイン、グリシテイン、ダイズイン、ゲニスチン、グリシチン、6”−O−マロニルダイズイン、6”−O−マロニルゲニスチン、6”−O−マロニルグリシチン、6”−O−アセチルダイズイン、6”−O−アセチルゲニスチン、6”−O−アセチルグリシチンや納豆にみられる6”−O−サクシニルダイズイン、6”−O−サクシニルゲニスチン、6”−O−サクシニルグリシチンおよびプェラリンなどが含まれる。なお。上記の各種イソフラボンは、本発明において、単独であるいは二種以上併せて用いられる。
濃度の高いイソフラボンを使用するため大豆や大豆食品、大豆胚軸、葛根なだの抽出物やその精製物を用いることも可能である。イソフラボンを抽出する溶媒は、特に限定されるものではないが、水またはエタノールなどのアルコールを用いるのが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過などを使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用しても良いが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用しても良い。
本発明に用いるラズベリーケトンは、特に限定されるものではないが、採取が容易で、かつ安全性等の観点から、ラズベリー由来のラズベリーケトンを用いることが望ましい。また、本発明に用いるカプシエイトも、特に限定されるものではないが、採取が容易で、かつ安全性等の観点より、唐辛子から選抜育種された品種「CH−19甘」を用いることが望ましい。
なお、上記ラズベリーケトンおよびカプシエイトは、ラズベリーや、上記特定の唐辛子品種を粉砕、粉末化したものをそのまま使用することもできるが、濃度の高いラズベリーケトンやカプシエイトを用いるため、その抽出物やその精製物を用いることも可能である。ラズベリーケトンやカプシエイトを抽出する溶媒は、特に限定されるものではないが、水またはエタノールなどのアルコールを用いるのが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過などを使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用しても良いが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用しても良い。
また、本発明で使用しているカプシエイトは、カプサイシンを使用してもよいし、一般的に栽培されている品種の唐辛子またはその抽出物を使用してもよいが、摂取した際、生体への刺激が強く、長期的、日常的に全ての人が利用することは難しい。よって刺激の少ないとされているカプシエイトを利用することが望ましい。
本発明に用いるグルコン酸は、特に限定されるものではないが、摂取が容易でかつ安全性等の観点から、蜂蜜もしくはローヤルゼリー由来のグルコン酸を用いることが望ましい。その他には味噌、酢などを利用しても良い。さらに、本発明に用いるクロロゲン酸も、特に限定されるものではないが、採取が容易でかつ安全性等の観点から、コーヒー豆由来のクロロゲン酸を用いることが望ましい。
なお、上記グルコン酸およびクロロゲン酸は、蜂蜜やローヤルゼリー、コーヒー豆を粉砕、粉末化したものをそのまま使用することもできるが、濃度の高いグルコン酸やクロロゲン酸を用いるため、その抽出物やその精製物を用いることも可能である。グルコン酸やクロロゲン酸を抽出する溶媒は、特に限定されるものではないが、水またはエタノール等のアルコールを用いることが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過等を使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用してもよいが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用してもよい。
本発明で用いるグルコン酸は、グルコン酸塩として、グルコン酸カルシウム、グルコン酸カリウム、グルコン酸銅、グルコン酸ナトリウム、グルコン酸マグネシウム、およびグルコン酸マンガン、などを用いることも可能である。
本発明で用いるカカオポリフェノールは、カカオを使用した食品、例えばチョコレートやココアなどより摂取することもできる。また、濃度の高いカカオポリフェノールを用いるため、その抽出物やその精製物を用いることも可能である。カカオポリフェノールを抽出する溶媒は、特に特に限定されるものではないが、水またはエタノール等のアルコールを用いることが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過等を使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用してもよいが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用してもよい。
本発明で用いる八丁味噌は、愛知県岡崎市を中心に作られている。豆味噌を2年以上熟成させていることを特徴とするものである。八丁味噌そのものを摂取してもよいし、八丁味噌を利用し調理した味噌汁など各種加工食品を摂取しても良い。また八丁味噌の抽出物を利用しても良い。抽出する溶媒は、特に限定されるものではないが、水またはエタノール等のアルコールを用いることが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過等を使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用してもよいが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用してもよい。
本発明の組成物は、上述のようにして得られたイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の少なくとも一つと、イソチオシアネート類とを必須成分とするものであり、これらを混合したものをそのまま直接使用してもいが、一般には、これらを、適当な液状担体に溶解あるいは分散させたり、適当な粉末担体に混合させたものを使用する。
そして、上記イソチオシアネート類が有効成分となり得るための含有量は、通常、液剤では0.0001~0.5重量%(以下、「%」と略す)の範囲であると好適であり、粉剤の場合は0.001~20%の範囲であると好適であり、粒剤の場合は0.001~10%の範囲であると好適である。イソフラボンが有効成分となり得るための含有量は、通常、液剤では0.001~0.5重量%(以下、「%」と略す)の範囲であると好適であり、粒剤の場合は0.01~80%の範囲であると好適であり、粒剤の場合は0.01~40%の範囲であると好適である。他方、上記ラズベリーケトンが有効成分となり得るための含有量は、通常、液剤では0.05~20%の範囲であると好適であり、粉剤の場合は0.05~100%の範囲であると好適であり、粒剤の場合は0.05~100%の範囲であると好適である。
また、上記カプシエイトが有効成分となり得るための含有量は、通常、液剤では0.0001~0.05%の範囲であると好適であり、粉剤の場合は0.0001~5%の範囲であると好適であり、粒剤の場合は0.0001~5%の範囲であると好適である。
さらに、上記グルコン酸が有効成分となり得るための含有量は、通常、液剤では0.05~10%の範囲であると好適であり、粉剤の場合は0.05~20%の範囲であると好適であり、粒剤の場合は0.05~10%の範囲であると好適である。
また、上記クロロゲン酸が有効成分となり得るための含有量は、通常、液剤では0.05~20%の範囲であると好適であり、粉剤の場合は0.05~10%の範囲であると好適であり、粒剤の場合は0.05~10%の範囲であると好適である。また、上記カカオポリフェノールが有効成分となり得るための含有量は、通常、液剤では0.5~20%の範囲であると好適であり、粉剤の場合は0.5~10%の範囲であると好適であり、粒剤の場合は0.5~10%の範囲であると好適である。
また、上記八丁味噌が有効成分となり得るための含有量は、通常、液剤では10~100%の範囲であると好適であり、粉剤の場合は20~50%の範囲であると好適であり、粒剤の場合は20~50%の範囲であると好適である。
そして、本発明においては、上記イソチオシアネート類と、上記イソフラボン等(イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、八丁味噌)との割合が重要であり、イソチオシアネート類:イソフラボン=1:1~1:1000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:イソフラボン=1:10~1:500の重量比の範囲である。また、イソチオシアネート類:ラズベリーケトン1:1~1:10000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:ラズベリーケトン1:100~1:6000の重量比の範囲である。また、イソチオシアネート類:カプシエイト=100:1~1:100の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:カプシエイト=20:1~1:20の重量比の範囲である。
さらに、イソチオシアネート類:グルコン酸=10:1~1:1000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:グルコン酸=1:1~1:200の重量比の範囲である。
また、イソチオシアネート類:クロロゲン酸=10:1~1:1000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:クロロゲン酸=1:1~1:200の重量比の範囲である。さらに、イソチオシアネート類:カカオポリフェノール=10:1~1:2000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:カカオポリフェノール=1:40~1:400の重量比の範囲である。また、イソチオシアネート類:八丁味噌=1:10~1:50000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:八丁味噌=1:600~1:6000の重量比の範囲である。すなわち、このような割合で双方が含有していると、双方の相乗効果により、本発明において要求されるカルシトニン遺伝子関連ペプチドの産生および放出促進作用が効果的に得られるようになるからである。なお、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌は、上記範囲内において併用することも可能である。
本発明の可食性組成物は、人間のみでなく、ペットや家畜等の動物においても、人間に投与した際にみられる前述の作用効果と同様の作用効果が期待されるものである。そして、その投与量は投与対象とする生物の違い、前述の各種作用効果のうちのいずれを得ることを目的とするのかといった違い、投与される者の性別、体重、年齢等の条件に応じて適宜設定される。例えば、成人に対しては上記イソフラボン等とイソチオシアネート類との混合物を1日あたり10~5000mgとなるよう、数回に分けて投与することができる。また、ペットや家畜等の動物においては、動物用飼料に上記混合物を0.001~5%の範囲で含有させ、1日当たり1~5000mg/kg体重の範囲となるよう投与するのが好ましい。
本発明の組成物は、それ単独で摂取することも可能であるが、各種飲食品あるいは医薬品に添加して使用することもできる。具体的には、清涼飲料水、茶飲料、ドリンク剤、アルコール飲料等の液体食品、果子、パン類、麺類、調味料等の固形食品、粉末状、顆粒状、カプセル状、錠剤等の医薬品・医薬部外品等に添加する。
本発明の組成物は、含有するイソチオシアネート類の香りを嗅ぐことまたは揮発したイソチオシアネート類に曝露することによっても、経口摂取した場合や塗布した場合と全く同様の効果を得ることが可能である。具体敵意にはアロマオイル、芳香剤、香水の日用品、香粧品類、香料または繊維や樹脂などに配合し、成分を揮発させることにより利用できる。
本発明において、揮発させたイソチオシアネートに曝露する場合、その濃度は限定されないが、人が認識できる程度から刺激や不快感のない程度に収めることが望ましい。またその濃度と効果には特に関係がない。
本発明において、アロマオイル、芳香剤、香水等の日用品、香粧品類、香料または繊維や樹脂などに配合し、イソチオシアネート類を揮発させて利用する場合、その他に配合する香気成分、香料などは自由に選択でき、その効果に悪影響をおよぼすことはない。使いやすい好みの香りに調合するなどして利用できる。
以下、本発明を実施例によって具体的に説明する。 Hereinafter, the present invention will be specifically described.
As described above, the composition of the present invention is a combination of isothiocyanates with at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acids, cocoa polyphenols, and haccho miso. And each of these components as an essential component. Such a configuration significantly promotes the production and release of calcitonin gene-related peptide and promotes the secretion of IGF-1. Here, the essential component refers to an optional component, and refers to a component which is necessarily contained in the constitution, and is not subject to quantitative restriction.
The isothiocyanates used in the present invention are 4-methylsulfinylbutyl isothiocyanate, 5-methylsulfinylpentyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate, 7-methylsulfinylheptyl isothiocyanate, 8-methylsulfinyloctyl isothiocyanate, Allyl isothiocyanate, secondary butyl isothiocyanate, 3-butenyl isothiocyanate, 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 5-methyl thiopentyl isothiocyanate, 6-methyl thiohexyl isothiocyanate, 7-methyl thioheptyl isothiocyanate , 8-Methylthiooctyl isothiocyanate, β-phenethyl isothiocyanate, benzyl isothio Aneto, phenyl isothiocyanate, and phenethyl isothiocyanate and the like are used in combination these alone, or plural kinds. However, the isothiocyanates that can be used in the present invention are not limited to the above compounds, and all isothiocyanates can be used as a raw material.
The above-mentioned isothiocyanates are also effective in chemically synthesized ones, and the effect is not different depending on the synthesis method and the source material, and they do not affect the present invention at all.
The chemical synthesis of isothiocyanates is specifically described as follows.
In principle, it follows the method of Kiaer et al. (Kiaer et al. Acta Chem. Scand, 11, 1298, 1957). Using ω-chloroalkenol as the starting material and refluxing with CH 3 -SNa, ω-methylthioalkenol is obtained to act on SOCl 2 to obtain ω-chloroalkenol methyl sulfide.
Next, an amino group is introduced using the Gabriel method to form N- (ω-methylthioalkyl) -phthalimide, to which hydrazine hydrate is added and refluxed to obtain ω-methylthioalkylamine. Furthermore, according to the method of Li et al. (Lietal. J. Org. Chem., 62, 4539, 1997), the methylthio group is oxidized with mCPBA of ω-methylthioalkylisothiocyanate obtained via lautim disulfide, ω Methylsulfinylalkyl isothiocyanate is obtained.
In the present invention, isothiocyanates can be obtained from cruciferous plants mainly from natural resources. Moreover, although the method includes grinding or grating treatment, extraction treatment with a solvent, and drying treatment singly or in combination, the method is not limited at all in the present invention.
Examples of the raw materials containing the above-mentioned isothiocyanates include the following. For example, Batissidae (Bataceae), Brassicaceae (Brassicaceae), Breschnadidae (Bretschneideraceae), Citrusaceae (Capparaceae), Papaya (Caricaceae), Euphorbiaceae (Euphorbiaceae), Gyrostemonidae (Gyrostemonaceae), Limnantes ( Limnanthaceae), Wasabinaceae (Moringaceae), Pentadipiprandaceae (Pentadiplandraceae), Phytolaccidae (Phytolaccaceae), Tobellanaceae (Pittosporaceae), Prunellanaceae (Resedaceae), Salvadoriaceae (Salvadoraceae), Touariaceae (Tovar) plants of the family Luceidae (Tropaeolaceae), for example, Batis maritima (Japanese name unknown), wasabi (Wasabia japonica), horseradish (Armoracia rusticana), mustard (Brassica juncea), broccoli (Brassica oleracea var. italica) ), Arabidopsis thaliana, Capsella bursa-pastoris, Watercress (Nasturtium officinale), Bretschneidera sinensis (Japanese name unknown), Caper (Capparis spinosa), Papaya (Carica papaya), Drypetes rox urghii (alias); Putranjiva roxburghii (Japanese name unknown), Tersonia brevipes (Japanese name unknown), Limnanthes douglasii (Japanese name unknown), Japanese horseradish (Moringa oleifera), Pentadiplandra brazzeana (Japanese name unknown), pokemon pokebo (Phytolacca) Bursaris spinosa var. Incana (Japanese name unknown), Shinobumokusou (Reseda alba), Salvadora persica (Japanese name unknown), Tovaria pendula (Japanese name unknown), Kumquat deer (Tropaeolum majus) etc. can be used. However, the isothiocyanates which can be used in the present invention are not limited to those obtained from the above-mentioned plant species, and all natural resources containing isothiocyanates can be used as a raw material.
On the other hand, the origin of isoflavones used in the present invention is not particularly limited, and examples thereof include soybean seeds, soya root and foods using them. Among them, soybean hypocotyl is advantageous because it contains a large amount of isoflavone. It is also possible to use foods such as natto.
Among the above isoflavones, daidzein, genistein, glycitein, soy in, genistin, glycitin, 6 ′ ′-O-malonyl soyin, 6 ′ ′-O-malonylgenistin, 6 ′ ′-O-malonylglycitin, 6 ′ ′-O-acetyl soy In, 6 ′ ′-O-acetylgenistin, 6 ′ ′-O-acetylglycitin and 6 ′ ′-O-succinylsaidsine found in natto, 6 ′ ′-O-succinilgenistin, 6 ′ ′-O-succinylglycitin and puerarin In the present invention, the above-mentioned various isoflavones are used alone or in combination of two or more.
It is also possible to use soy and soy foods, soy hypocotyls, extracts of soda rootstock and purified products thereof because high concentrations of isoflavones are used. The solvent for extracting isoflavones is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. In addition, as a method of purification, although it is possible to use a synthetic adsorbent, ion exchange resin, ultrafiltration or the like, it is not particularly limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
The raspberry ketone used in the present invention is not particularly limited, but it is desirable to use raspberry-derived raspberry ketone from the viewpoint of easy collection and safety. Also, the capsiate used in the present invention is not particularly limited, but it is desirable to use the variety "CH-19 sweet" selected and bred from pepper, from the viewpoint of easy collection and safety.
The above raspberry ketone and capsiate may be used as they are by grinding raspberry or the above-mentioned specific pepper variety as it is, but since raspberry ketone or capsiate having a high concentration is used, the extract or its purified product may be used. It is also possible to use. The solvent for extracting raspberry ketone and capsiate is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. In addition, as a method of purification, although it is possible to use a synthetic adsorbent, ion exchange resin, ultrafiltration or the like, it is not particularly limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
In addition, as the capsiate used in the present invention, capsaicin may be used, or peppers of generally grown varieties or extracts thereof may be used. Stimulative, long-term, it is difficult for all people to use on a daily basis. Therefore, it is desirable to use capsiate which is considered to be less irritating.
Although gluconic acid used in the present invention is not particularly limited, it is desirable to use gluconic acid derived from honey or royal jelly from the viewpoint of easy intake and safety. In addition, miso and vinegar may be used. Furthermore, the chlorogenic acid used in the present invention is not particularly limited, but it is desirable to use coffee bean-derived chlorogenic acid from the viewpoint of easy collection and safety.
The above gluconic acid and chlorogenic acid can be used by grinding honey and royal jelly or coffee beans as it is, but using gluconic acid and chlorogenic acid with high concentration, their extracts and their purification It is also possible to use a thing. The solvent for extracting gluconic acid and chlorogenic acid is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. Moreover, although the method of refinement | purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
As gluconic acid used in the present invention, it is also possible to use calcium gluconate, potassium gluconate, copper gluconate, sodium gluconate, magnesium gluconate, manganese gluconate and the like as gluconate.
The cocoa polyphenols used in the present invention can also be taken from foods that use cocoa, such as chocolate and cocoa. Moreover, in order to use a high concentration cocoa polyphenol, it is also possible to use its extract and its refinement | purification thing. The solvent for extracting cocoa polyphenol is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. Moreover, although the method of refinement | purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
Hatcho miso used in the present invention is mainly made in Okazaki City, Aichi Prefecture. The soybean miso is characterized by being aged for 2 years or more. You may ingest Hachicho miso itself, or you may ingest various processed foods such as miso soup prepared using Haccho miso. Alternatively, an extract of Haccho Miso may be used. The solvent to be extracted is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. Moreover, although the method of refinement | purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
The composition of the present invention comprises, as essential components, isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol, and at least one of hachicho-miso and the isothiocyanates obtained as described above. A mixture of these may be used directly as it is, but generally, a solution or dispersion of these in a suitable liquid carrier or a mixture in a suitable powder carrier is used.
And, the content for the above-mentioned isothiocyanates to become an active ingredient is usually preferably in the range of 0.0001 to 0.5% by weight (hereinafter abbreviated as "%") in the liquid form, and it is preferable In the case of 0.001 to 20% in the case of granules, it is preferable that the range of 0.001 to 10% is in the case of granules. The content of isoflavone as an active ingredient is generally preferably 0.001 to 0.5% by weight (hereinafter abbreviated as "%") in the liquid preparation, and 0. The range of 01 to 80% is preferable, and in the case of granules, the range of 0.01 to 40% is preferable. On the other hand, the content for the raspberry ketone to be an active ingredient is usually preferably in the range of 0.05 to 20% in the solution, and preferably in the range of 0.05 to 100% in the case of powders. In the case of granules, it is preferably in the range of 0.05 to 100%.
In addition, the content for the above-mentioned capsiate to become an active ingredient is usually suitably in the range of 0.0001 to 0.05% in the liquid preparation and in the range of 0.0001 to 5% in the dust preparation. In the case of granules, it is preferable to be in the range of 0.0001 to 5%.
Furthermore, the content for the above-mentioned gluconic acid to become an active ingredient is usually suitably in the range of 0.05 to 10% in the liquid preparation, and in the range of 0.05 to 20% in the powder preparation In the case of granules, the preferred range is 0.05 to 10%.
In addition, the content for the chlorogenic acid to be an active ingredient is generally preferably in the range of 0.05 to 20% in the liquid preparation and in the range of 0.05 to 10% in the dust In the case of granules, the preferred range is 0.05 to 10%. In addition, the content for the above-mentioned cocoa polyphenol to become an active ingredient is usually suitably in the range of 0.5 to 20% in the liquid preparation and in the range of 0.5 to 10% in the case of powders. In the case of granules, it is preferable that it is in the range of 0.5 to 10%.
In addition, the content for the above-mentioned Haccho miso to become an active ingredient is usually suitable in the range of 10 to 100% in the liquid preparation, and preferably in the range of 20 to 50% in the powder preparation, In the case of granules, it is preferable that it is in the range of 20 to 50%.
In the present invention, the ratio of the above-mentioned isothiocyanates to the above-mentioned isoflavones etc (isoflavones, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, haccho miso) is important, and isothiocyanates: isoflavone = 1. It is preferable to contain in a weight ratio of 1: 1 to 1: 1000, and more preferable is a range of a weight ratio of isothiocyanates: isoflavone = 1: 10 to 1: 500. Further, it is preferable to contain isothiocyanates: raspberry ketone in a weight ratio of 1: 1 to 1: 10000, and more preferably in a weight ratio range of isothiocyanates: raspberry ketone 1: 100 to 1: 6000. Further, it is preferable to contain isothiocyanates: capsiate in a weight ratio of 100: 1 to 1: 100, and more preferably in a weight ratio range of isothiocyanates: capsiate = 20: 1 to 1:20. .
Furthermore, it is preferable to contain isothiocyanates: gluconic acid in a weight ratio of 10: 1 to 1: 1000, and more preferably, a range of a weight ratio of isothiocyanates: gluconic acid = 1: 1 to 1: 200. It is.
Further, it is preferable to contain isothiocyanates: chlorogenic acid = 10: 1 to 1: 1000 in weight ratio, and more preferably, isothiocyanates: chlorogenic acid = 1: 1 to 1: 200 in weight ratio range It is. Further, it is preferable to contain isothiocyanates: cocoa polyphenol = 10: 1 to 1: 2000 in weight ratio, and more preferably, a range of isothiocyanates: cocoa polyphenol = 1: 40 to 1: 400 in weight ratio It is. Moreover, it is preferable to contain it by the weight ratio of isothiocyanates: haccho miso = 1: 10-1: 50000, More preferably, the range of the weight ratio of isothiocyanates: haccho miso = 1: 600-1: 6000 It is. That is, when both are contained in such a proportion, the synergistic effect of both can effectively obtain the calcitonin gene-related peptide production and release promoting action required in the present invention. In addition, isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol, and Haccho miso can be used in combination within the above range.
The edible composition of the present invention is expected to have the same action and effect as the above-mentioned action and effect seen when administered to humans not only in humans but also in animals such as pets and livestock. And, depending on conditions such as the sex, weight, age, etc. of the person to be administered, the dose differs depending on the difference between the organisms to be administered and which one of the various effects described above is to be obtained. It is set appropriately. For example, for an adult, the mixture of the above isoflavones etc. and isothiocyanates can be divided into several doses so as to be 10 to 5000 mg per day. In addition, in animals such as pets and livestock, it is preferable that the above-mentioned mixture is contained in the animal feed in the range of 0.001 to 5%, and is administered in the range of 1 to 5000 mg / kg body weight per day.
The composition of the present invention can be taken alone, but can also be used by being added to various food products or medicines. Specifically, liquid foods such as soft drinks, tea beverages, drinks, alcoholic beverages, solid foods such as fruits, breads, noodles, seasonings, etc., pharmaceuticals such as powders, granules, capsules and tablets Add to quasi-drugs etc.
The composition of the present invention can also obtain the same effect as taking it orally or applying it by sniffing the isothiocyanate contained or exposing it to volatilized isothiocyanates. . Specifically, it can be used by blending it into an aroma oil, a fragrance, daily necessities for perfume, cosmetics, perfumes, fibers or resins, etc. and volatilizing the components.
In the present invention, when exposed to volatilized isothiocyanate, the concentration is not limited, but it is desirable that the concentration is within the range that can be recognized by human being without causing irritation or discomfort. There is no particular relationship between the concentration and the effect.
In the present invention, when it is added to aromatic oils, fragrances, daily necessities such as perfumes, cosmetics, perfumes, fibers or resins, etc. and volatilized isothiocyanates, aroma components, perfumes, etc. It can be chosen freely and does not adversely affect its effect. It can be used by blending it into a flavor that is easy to use.
Hereinafter, the present invention will be specifically described by way of examples.
本発明の組成物は、先にも述べたように、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌からなる群から選ばれた少なくとも一つと、イソチオシアネート類との組み合わせを特徴とするものであり、これら各成分を必須成分として含有するものである。このような構成によって、カルシトニン遺伝子関連ペプチドの産生および放出が著明に促進され、IGF−1の分泌が促進されるようになる。ここで、必須成分とは、任意成分に対するものであって、構成上必ず含有される成分のことをいい、量的な制約は受けない。
本発明に用いられるイソチオシアネート類は、4−メチルスルフィニルブチルイソチオシアネート、5−メチルスルフィニルペンチルイソチオシアネート、6−メチルスルフィニルヘキシルイソチオシアネート、7−メチルスルフィニルヘプチルイソチオシアネート、8−メチルスルフィニルオクチルイソチオシアネート、アリルイソチオシアネート、第2級ブチルイソチオシアネート、3−ブテニルイソチオシアネート、4−ペンテニルイソチオシアネート、5−ヘキセニルイソチオシアネート、5−メチルチオペンチルイソチオシアネート、6−メチルチオヘキシルイソチオシアネート、7−メチルチオヘプチルイソチオシアネート、8−メチルチオオクチルイソチオシアネート、β−フェネチルイソチオシアネート、ベンジルイソチオシアネート、フェニルイソチオシアネート、およびフェネチルイソチオシアネート等が挙げられ、これらを単独で、あるいは複数種を組み合わせて使用される。ただし、本発明で使用できるイソチオシアネート類は、上記の化合物に限定されるものではなく、イソチオシアネート類全てが原料として使用できる。
上述のイソチオシアネート類は、化学的に合成されたものにおいても有効であり、その合成法、起源物質により効果に違いは無く、本発明には全く影響をおよぼすものではない。
イソチオシアネート類の化学合成法を具体的に説明すると、以下のとおりである。
原理的にはKiaer等の方法にしたがう。(Kiaer etal.Acta Chem.Scand,11,1298,1957年)。出発物質としてω−クロロアルケノールを用い、CH3−SNaと還流してω−メチルチオアルケノールを得、これにSOCl2を作用させてω−クロロアルケノールメチルサルファイドを得る。
次にガブリエル法を用いてアミノ基を導入し、N−(ω−メチルチオアルキル)−フタルイミドを生成し、これらにヒドラジン水化物を加えて還流し、ω−メチルチオアルキルアミンを得る。さらに、Li等の方法(Lietal.J.Org.Chem.,62,4539,1997年)にしたがい、ラウチムジスルフィドを経て得られたω−メチルチオアルキルイソチオシアネートをmCPBAでメチルチオ基を酸化し、ω−メチルスルフィニルアルキルイソチオシアネートを得る。
本発明において、イソチオシアネート類はアブラナ科植物を主として天然資源より得ることができる。また、その方法としては粉砕またはすりおろし処理、溶媒による抽出処理、乾燥処理を単独または組み合わせ処理が挙げられるが、本発明に関して、その方法は一切限定されるものではない。
上述のイソチオシアネート類を含む原料としては以下のようなものが挙げられる。例えば、バティス科(Bataceae)、アブラナ科(Brassicaceae)、ブレッシュネイデラ科(Bretschneideraceae)、フウチョウソウ科(Capparaceae)、パパイア科(Caricaceae)、トウダイグサ科(Euphorbiaceae)、ギロステモン科(Gyrostemonaceae)、リムナンテス科(Limnanthaceae)、ワサビノキ科(Moringaceae)、ペンタディプランドラ科(Pentadiplandraceae)、ヤマゴボウ科(Phytolaccaceae)、トベラ科(Pittosporaceae)、モクセイソウ科(Resedaceae)、サルウァドラ科(Salvadoraceae)、トウァリア科(Tovariaceae)、ノウゼンハレン科(Tropaeolaceae)、の植物、例えば、Batis maritima(和名不詳)、本わさび(Wasabia japonica)、西洋わさび(Armoracia rusticana)、からし(Brassica juncea)、ブロッコリー(Brassica oleracea var.italica)、シロイヌナズナ(Arabidopsis thaliana)、ナズナ(Capsella bursa−pastoris)、クレソン(Nasturtium officinale)、Bretschneidera sinensis(和名不詳)、ケッパー(Capparis spinosa)、パパイア(Carica papaya)、Drypetes roxburghii(別名);Putranjiva roxburghii(和名不詳)、Tersonia brevipes(和名不詳)、Limnanthes douglasii(和名不詳)、ワサビノキ(Moringa oleifera)、Pentadiplandra brazzeana(和名不詳)、ヨウシュヤマゴボウ(Phytolacca americana)、Bursaris spinosa var.incana(和名不詳)、シノブモクセイソウ(Reseda alba)、Salvadora persica(和名不詳)、Tovaria pendula(和名不詳)、キンレンカ(Tropaeolum majus)等が使用できる。ただし、本発明で使用できるイソチオシアネート類は、上記の植物種から得られるものに限定されるものではなく、イソチオシアネート類を含有する全ての天然資源が原料として使用できる。
一方、本発明に用いるイソフラボンの由来は、特に限定されるものではなく、例えば、大豆種子、葛根およびそれらを用いた食品などが挙げられる。なかでも大豆の胚軸にはイソフラボンが多量に含まれるため都合が良い。また、納豆などの食品を用いることも可能である。
上記イソフラボンには、ダイゼイン、ゲニステイン、グリシテイン、ダイズイン、ゲニスチン、グリシチン、6”−O−マロニルダイズイン、6”−O−マロニルゲニスチン、6”−O−マロニルグリシチン、6”−O−アセチルダイズイン、6”−O−アセチルゲニスチン、6”−O−アセチルグリシチンや納豆にみられる6”−O−サクシニルダイズイン、6”−O−サクシニルゲニスチン、6”−O−サクシニルグリシチンおよびプェラリンなどが含まれる。なお。上記の各種イソフラボンは、本発明において、単独であるいは二種以上併せて用いられる。
濃度の高いイソフラボンを使用するため大豆や大豆食品、大豆胚軸、葛根なだの抽出物やその精製物を用いることも可能である。イソフラボンを抽出する溶媒は、特に限定されるものではないが、水またはエタノールなどのアルコールを用いるのが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過などを使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用しても良いが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用しても良い。
本発明に用いるラズベリーケトンは、特に限定されるものではないが、採取が容易で、かつ安全性等の観点から、ラズベリー由来のラズベリーケトンを用いることが望ましい。また、本発明に用いるカプシエイトも、特に限定されるものではないが、採取が容易で、かつ安全性等の観点より、唐辛子から選抜育種された品種「CH−19甘」を用いることが望ましい。
なお、上記ラズベリーケトンおよびカプシエイトは、ラズベリーや、上記特定の唐辛子品種を粉砕、粉末化したものをそのまま使用することもできるが、濃度の高いラズベリーケトンやカプシエイトを用いるため、その抽出物やその精製物を用いることも可能である。ラズベリーケトンやカプシエイトを抽出する溶媒は、特に限定されるものではないが、水またはエタノールなどのアルコールを用いるのが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過などを使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用しても良いが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用しても良い。
また、本発明で使用しているカプシエイトは、カプサイシンを使用してもよいし、一般的に栽培されている品種の唐辛子またはその抽出物を使用してもよいが、摂取した際、生体への刺激が強く、長期的、日常的に全ての人が利用することは難しい。よって刺激の少ないとされているカプシエイトを利用することが望ましい。
本発明に用いるグルコン酸は、特に限定されるものではないが、摂取が容易でかつ安全性等の観点から、蜂蜜もしくはローヤルゼリー由来のグルコン酸を用いることが望ましい。その他には味噌、酢などを利用しても良い。さらに、本発明に用いるクロロゲン酸も、特に限定されるものではないが、採取が容易でかつ安全性等の観点から、コーヒー豆由来のクロロゲン酸を用いることが望ましい。
なお、上記グルコン酸およびクロロゲン酸は、蜂蜜やローヤルゼリー、コーヒー豆を粉砕、粉末化したものをそのまま使用することもできるが、濃度の高いグルコン酸やクロロゲン酸を用いるため、その抽出物やその精製物を用いることも可能である。グルコン酸やクロロゲン酸を抽出する溶媒は、特に限定されるものではないが、水またはエタノール等のアルコールを用いることが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過等を使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用してもよいが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用してもよい。
本発明で用いるグルコン酸は、グルコン酸塩として、グルコン酸カルシウム、グルコン酸カリウム、グルコン酸銅、グルコン酸ナトリウム、グルコン酸マグネシウム、およびグルコン酸マンガン、などを用いることも可能である。
本発明で用いるカカオポリフェノールは、カカオを使用した食品、例えばチョコレートやココアなどより摂取することもできる。また、濃度の高いカカオポリフェノールを用いるため、その抽出物やその精製物を用いることも可能である。カカオポリフェノールを抽出する溶媒は、特に特に限定されるものではないが、水またはエタノール等のアルコールを用いることが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過等を使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用してもよいが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用してもよい。
本発明で用いる八丁味噌は、愛知県岡崎市を中心に作られている。豆味噌を2年以上熟成させていることを特徴とするものである。八丁味噌そのものを摂取してもよいし、八丁味噌を利用し調理した味噌汁など各種加工食品を摂取しても良い。また八丁味噌の抽出物を利用しても良い。抽出する溶媒は、特に限定されるものではないが、水またはエタノール等のアルコールを用いることが好ましい。また、精製の方法は、合成吸着剤やイオン交換樹脂、限外ろ過等を使用することが可能であるが、特に限定されるものではない。抽出液または精製液は、そのまま使用してもよいが、それらを濃縮した濃縮液、もしくは、抽出液または精製液を乾燥したあと粉末化したものを使用してもよい。
本発明の組成物は、上述のようにして得られたイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の少なくとも一つと、イソチオシアネート類とを必須成分とするものであり、これらを混合したものをそのまま直接使用してもいが、一般には、これらを、適当な液状担体に溶解あるいは分散させたり、適当な粉末担体に混合させたものを使用する。
そして、上記イソチオシアネート類が有効成分となり得るための含有量は、通常、液剤では0.0001~0.5重量%(以下、「%」と略す)の範囲であると好適であり、粉剤の場合は0.001~20%の範囲であると好適であり、粒剤の場合は0.001~10%の範囲であると好適である。イソフラボンが有効成分となり得るための含有量は、通常、液剤では0.001~0.5重量%(以下、「%」と略す)の範囲であると好適であり、粒剤の場合は0.01~80%の範囲であると好適であり、粒剤の場合は0.01~40%の範囲であると好適である。他方、上記ラズベリーケトンが有効成分となり得るための含有量は、通常、液剤では0.05~20%の範囲であると好適であり、粉剤の場合は0.05~100%の範囲であると好適であり、粒剤の場合は0.05~100%の範囲であると好適である。
また、上記カプシエイトが有効成分となり得るための含有量は、通常、液剤では0.0001~0.05%の範囲であると好適であり、粉剤の場合は0.0001~5%の範囲であると好適であり、粒剤の場合は0.0001~5%の範囲であると好適である。
さらに、上記グルコン酸が有効成分となり得るための含有量は、通常、液剤では0.05~10%の範囲であると好適であり、粉剤の場合は0.05~20%の範囲であると好適であり、粒剤の場合は0.05~10%の範囲であると好適である。
また、上記クロロゲン酸が有効成分となり得るための含有量は、通常、液剤では0.05~20%の範囲であると好適であり、粉剤の場合は0.05~10%の範囲であると好適であり、粒剤の場合は0.05~10%の範囲であると好適である。また、上記カカオポリフェノールが有効成分となり得るための含有量は、通常、液剤では0.5~20%の範囲であると好適であり、粉剤の場合は0.5~10%の範囲であると好適であり、粒剤の場合は0.5~10%の範囲であると好適である。
また、上記八丁味噌が有効成分となり得るための含有量は、通常、液剤では10~100%の範囲であると好適であり、粉剤の場合は20~50%の範囲であると好適であり、粒剤の場合は20~50%の範囲であると好適である。
そして、本発明においては、上記イソチオシアネート類と、上記イソフラボン等(イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、八丁味噌)との割合が重要であり、イソチオシアネート類:イソフラボン=1:1~1:1000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:イソフラボン=1:10~1:500の重量比の範囲である。また、イソチオシアネート類:ラズベリーケトン1:1~1:10000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:ラズベリーケトン1:100~1:6000の重量比の範囲である。また、イソチオシアネート類:カプシエイト=100:1~1:100の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:カプシエイト=20:1~1:20の重量比の範囲である。
さらに、イソチオシアネート類:グルコン酸=10:1~1:1000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:グルコン酸=1:1~1:200の重量比の範囲である。
また、イソチオシアネート類:クロロゲン酸=10:1~1:1000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:クロロゲン酸=1:1~1:200の重量比の範囲である。さらに、イソチオシアネート類:カカオポリフェノール=10:1~1:2000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:カカオポリフェノール=1:40~1:400の重量比の範囲である。また、イソチオシアネート類:八丁味噌=1:10~1:50000の重量比で含有していると好ましく、より好ましくは、イソチオシアネート類:八丁味噌=1:600~1:6000の重量比の範囲である。すなわち、このような割合で双方が含有していると、双方の相乗効果により、本発明において要求されるカルシトニン遺伝子関連ペプチドの産生および放出促進作用が効果的に得られるようになるからである。なお、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌は、上記範囲内において併用することも可能である。
本発明の可食性組成物は、人間のみでなく、ペットや家畜等の動物においても、人間に投与した際にみられる前述の作用効果と同様の作用効果が期待されるものである。そして、その投与量は投与対象とする生物の違い、前述の各種作用効果のうちのいずれを得ることを目的とするのかといった違い、投与される者の性別、体重、年齢等の条件に応じて適宜設定される。例えば、成人に対しては上記イソフラボン等とイソチオシアネート類との混合物を1日あたり10~5000mgとなるよう、数回に分けて投与することができる。また、ペットや家畜等の動物においては、動物用飼料に上記混合物を0.001~5%の範囲で含有させ、1日当たり1~5000mg/kg体重の範囲となるよう投与するのが好ましい。
本発明の組成物は、それ単独で摂取することも可能であるが、各種飲食品あるいは医薬品に添加して使用することもできる。具体的には、清涼飲料水、茶飲料、ドリンク剤、アルコール飲料等の液体食品、果子、パン類、麺類、調味料等の固形食品、粉末状、顆粒状、カプセル状、錠剤等の医薬品・医薬部外品等に添加する。
本発明の組成物は、含有するイソチオシアネート類の香りを嗅ぐことまたは揮発したイソチオシアネート類に曝露することによっても、経口摂取した場合や塗布した場合と全く同様の効果を得ることが可能である。具体敵意にはアロマオイル、芳香剤、香水の日用品、香粧品類、香料または繊維や樹脂などに配合し、成分を揮発させることにより利用できる。
本発明において、揮発させたイソチオシアネートに曝露する場合、その濃度は限定されないが、人が認識できる程度から刺激や不快感のない程度に収めることが望ましい。またその濃度と効果には特に関係がない。
本発明において、アロマオイル、芳香剤、香水等の日用品、香粧品類、香料または繊維や樹脂などに配合し、イソチオシアネート類を揮発させて利用する場合、その他に配合する香気成分、香料などは自由に選択でき、その効果に悪影響をおよぼすことはない。使いやすい好みの香りに調合するなどして利用できる。
以下、本発明を実施例によって具体的に説明する。 Hereinafter, the present invention will be specifically described.
As described above, the composition of the present invention is a combination of isothiocyanates with at least one selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acids, cocoa polyphenols, and haccho miso. And each of these components as an essential component. Such a configuration significantly promotes the production and release of calcitonin gene-related peptide and promotes the secretion of IGF-1. Here, the essential component refers to an optional component, and refers to a component which is necessarily contained in the constitution, and is not subject to quantitative restriction.
The isothiocyanates used in the present invention are 4-methylsulfinylbutyl isothiocyanate, 5-methylsulfinylpentyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate, 7-methylsulfinylheptyl isothiocyanate, 8-methylsulfinyloctyl isothiocyanate, Allyl isothiocyanate, secondary butyl isothiocyanate, 3-butenyl isothiocyanate, 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 5-methyl thiopentyl isothiocyanate, 6-methyl thiohexyl isothiocyanate, 7-methyl thioheptyl isothiocyanate , 8-Methylthiooctyl isothiocyanate, β-phenethyl isothiocyanate, benzyl isothio Aneto, phenyl isothiocyanate, and phenethyl isothiocyanate and the like are used in combination these alone, or plural kinds. However, the isothiocyanates that can be used in the present invention are not limited to the above compounds, and all isothiocyanates can be used as a raw material.
The above-mentioned isothiocyanates are also effective in chemically synthesized ones, and the effect is not different depending on the synthesis method and the source material, and they do not affect the present invention at all.
The chemical synthesis of isothiocyanates is specifically described as follows.
In principle, it follows the method of Kiaer et al. (Kiaer et al. Acta Chem. Scand, 11, 1298, 1957). Using ω-chloroalkenol as the starting material and refluxing with CH 3 -SNa, ω-methylthioalkenol is obtained to act on SOCl 2 to obtain ω-chloroalkenol methyl sulfide.
Next, an amino group is introduced using the Gabriel method to form N- (ω-methylthioalkyl) -phthalimide, to which hydrazine hydrate is added and refluxed to obtain ω-methylthioalkylamine. Furthermore, according to the method of Li et al. (Lietal. J. Org. Chem., 62, 4539, 1997), the methylthio group is oxidized with mCPBA of ω-methylthioalkylisothiocyanate obtained via lautim disulfide, ω Methylsulfinylalkyl isothiocyanate is obtained.
In the present invention, isothiocyanates can be obtained from cruciferous plants mainly from natural resources. Moreover, although the method includes grinding or grating treatment, extraction treatment with a solvent, and drying treatment singly or in combination, the method is not limited at all in the present invention.
Examples of the raw materials containing the above-mentioned isothiocyanates include the following. For example, Batissidae (Bataceae), Brassicaceae (Brassicaceae), Breschnadidae (Bretschneideraceae), Citrusaceae (Capparaceae), Papaya (Caricaceae), Euphorbiaceae (Euphorbiaceae), Gyrostemonidae (Gyrostemonaceae), Limnantes ( Limnanthaceae), Wasabinaceae (Moringaceae), Pentadipiprandaceae (Pentadiplandraceae), Phytolaccidae (Phytolaccaceae), Tobellanaceae (Pittosporaceae), Prunellanaceae (Resedaceae), Salvadoriaceae (Salvadoraceae), Touariaceae (Tovar) plants of the family Luceidae (Tropaeolaceae), for example, Batis maritima (Japanese name unknown), wasabi (Wasabia japonica), horseradish (Armoracia rusticana), mustard (Brassica juncea), broccoli (Brassica oleracea var. italica) ), Arabidopsis thaliana, Capsella bursa-pastoris, Watercress (Nasturtium officinale), Bretschneidera sinensis (Japanese name unknown), Caper (Capparis spinosa), Papaya (Carica papaya), Drypetes rox urghii (alias); Putranjiva roxburghii (Japanese name unknown), Tersonia brevipes (Japanese name unknown), Limnanthes douglasii (Japanese name unknown), Japanese horseradish (Moringa oleifera), Pentadiplandra brazzeana (Japanese name unknown), pokemon pokebo (Phytolacca) Bursaris spinosa var. Incana (Japanese name unknown), Shinobumokusou (Reseda alba), Salvadora persica (Japanese name unknown), Tovaria pendula (Japanese name unknown), Kumquat deer (Tropaeolum majus) etc. can be used. However, the isothiocyanates which can be used in the present invention are not limited to those obtained from the above-mentioned plant species, and all natural resources containing isothiocyanates can be used as a raw material.
On the other hand, the origin of isoflavones used in the present invention is not particularly limited, and examples thereof include soybean seeds, soya root and foods using them. Among them, soybean hypocotyl is advantageous because it contains a large amount of isoflavone. It is also possible to use foods such as natto.
Among the above isoflavones, daidzein, genistein, glycitein, soy in, genistin, glycitin, 6 ′ ′-O-malonyl soyin, 6 ′ ′-O-malonylgenistin, 6 ′ ′-O-malonylglycitin, 6 ′ ′-O-acetyl soy In, 6 ′ ′-O-acetylgenistin, 6 ′ ′-O-acetylglycitin and 6 ′ ′-O-succinylsaidsine found in natto, 6 ′ ′-O-succinilgenistin, 6 ′ ′-O-succinylglycitin and puerarin In the present invention, the above-mentioned various isoflavones are used alone or in combination of two or more.
It is also possible to use soy and soy foods, soy hypocotyls, extracts of soda rootstock and purified products thereof because high concentrations of isoflavones are used. The solvent for extracting isoflavones is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. In addition, as a method of purification, although it is possible to use a synthetic adsorbent, ion exchange resin, ultrafiltration or the like, it is not particularly limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
The raspberry ketone used in the present invention is not particularly limited, but it is desirable to use raspberry-derived raspberry ketone from the viewpoint of easy collection and safety. Also, the capsiate used in the present invention is not particularly limited, but it is desirable to use the variety "CH-19 sweet" selected and bred from pepper, from the viewpoint of easy collection and safety.
The above raspberry ketone and capsiate may be used as they are by grinding raspberry or the above-mentioned specific pepper variety as it is, but since raspberry ketone or capsiate having a high concentration is used, the extract or its purified product may be used. It is also possible to use. The solvent for extracting raspberry ketone and capsiate is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. In addition, as a method of purification, although it is possible to use a synthetic adsorbent, ion exchange resin, ultrafiltration or the like, it is not particularly limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
In addition, as the capsiate used in the present invention, capsaicin may be used, or peppers of generally grown varieties or extracts thereof may be used. Stimulative, long-term, it is difficult for all people to use on a daily basis. Therefore, it is desirable to use capsiate which is considered to be less irritating.
Although gluconic acid used in the present invention is not particularly limited, it is desirable to use gluconic acid derived from honey or royal jelly from the viewpoint of easy intake and safety. In addition, miso and vinegar may be used. Furthermore, the chlorogenic acid used in the present invention is not particularly limited, but it is desirable to use coffee bean-derived chlorogenic acid from the viewpoint of easy collection and safety.
The above gluconic acid and chlorogenic acid can be used by grinding honey and royal jelly or coffee beans as it is, but using gluconic acid and chlorogenic acid with high concentration, their extracts and their purification It is also possible to use a thing. The solvent for extracting gluconic acid and chlorogenic acid is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. Moreover, although the method of refinement | purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
As gluconic acid used in the present invention, it is also possible to use calcium gluconate, potassium gluconate, copper gluconate, sodium gluconate, magnesium gluconate, manganese gluconate and the like as gluconate.
The cocoa polyphenols used in the present invention can also be taken from foods that use cocoa, such as chocolate and cocoa. Moreover, in order to use a high concentration cocoa polyphenol, it is also possible to use its extract and its refinement | purification thing. The solvent for extracting cocoa polyphenol is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. Moreover, although the method of refinement | purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
Hatcho miso used in the present invention is mainly made in Okazaki City, Aichi Prefecture. The soybean miso is characterized by being aged for 2 years or more. You may ingest Hachicho miso itself, or you may ingest various processed foods such as miso soup prepared using Haccho miso. Alternatively, an extract of Haccho Miso may be used. The solvent to be extracted is not particularly limited, but it is preferable to use water or an alcohol such as ethanol. Moreover, although the method of refinement | purification can use synthetic adsorbent, ion exchange resin, ultrafiltration etc., it is not specifically limited. The extract or purified liquid may be used as it is, or a concentrate obtained by concentrating them or a powder obtained by drying the extract or purified liquid may be used.
The composition of the present invention comprises, as essential components, isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol, and at least one of hachicho-miso and the isothiocyanates obtained as described above. A mixture of these may be used directly as it is, but generally, a solution or dispersion of these in a suitable liquid carrier or a mixture in a suitable powder carrier is used.
And, the content for the above-mentioned isothiocyanates to become an active ingredient is usually preferably in the range of 0.0001 to 0.5% by weight (hereinafter abbreviated as "%") in the liquid form, and it is preferable In the case of 0.001 to 20% in the case of granules, it is preferable that the range of 0.001 to 10% is in the case of granules. The content of isoflavone as an active ingredient is generally preferably 0.001 to 0.5% by weight (hereinafter abbreviated as "%") in the liquid preparation, and 0. The range of 01 to 80% is preferable, and in the case of granules, the range of 0.01 to 40% is preferable. On the other hand, the content for the raspberry ketone to be an active ingredient is usually preferably in the range of 0.05 to 20% in the solution, and preferably in the range of 0.05 to 100% in the case of powders. In the case of granules, it is preferably in the range of 0.05 to 100%.
In addition, the content for the above-mentioned capsiate to become an active ingredient is usually suitably in the range of 0.0001 to 0.05% in the liquid preparation and in the range of 0.0001 to 5% in the dust preparation. In the case of granules, it is preferable to be in the range of 0.0001 to 5%.
Furthermore, the content for the above-mentioned gluconic acid to become an active ingredient is usually suitably in the range of 0.05 to 10% in the liquid preparation, and in the range of 0.05 to 20% in the powder preparation In the case of granules, the preferred range is 0.05 to 10%.
In addition, the content for the chlorogenic acid to be an active ingredient is generally preferably in the range of 0.05 to 20% in the liquid preparation and in the range of 0.05 to 10% in the dust In the case of granules, the preferred range is 0.05 to 10%. In addition, the content for the above-mentioned cocoa polyphenol to become an active ingredient is usually suitably in the range of 0.5 to 20% in the liquid preparation and in the range of 0.5 to 10% in the case of powders. In the case of granules, it is preferable that it is in the range of 0.5 to 10%.
In addition, the content for the above-mentioned Haccho miso to become an active ingredient is usually suitable in the range of 10 to 100% in the liquid preparation, and preferably in the range of 20 to 50% in the powder preparation, In the case of granules, it is preferable that it is in the range of 20 to 50%.
In the present invention, the ratio of the above-mentioned isothiocyanates to the above-mentioned isoflavones etc (isoflavones, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, haccho miso) is important, and isothiocyanates: isoflavone = 1. It is preferable to contain in a weight ratio of 1: 1 to 1: 1000, and more preferable is a range of a weight ratio of isothiocyanates: isoflavone = 1: 10 to 1: 500. Further, it is preferable to contain isothiocyanates: raspberry ketone in a weight ratio of 1: 1 to 1: 10000, and more preferably in a weight ratio range of isothiocyanates: raspberry ketone 1: 100 to 1: 6000. Further, it is preferable to contain isothiocyanates: capsiate in a weight ratio of 100: 1 to 1: 100, and more preferably in a weight ratio range of isothiocyanates: capsiate = 20: 1 to 1:20. .
Furthermore, it is preferable to contain isothiocyanates: gluconic acid in a weight ratio of 10: 1 to 1: 1000, and more preferably, a range of a weight ratio of isothiocyanates: gluconic acid = 1: 1 to 1: 200. It is.
Further, it is preferable to contain isothiocyanates: chlorogenic acid = 10: 1 to 1: 1000 in weight ratio, and more preferably, isothiocyanates: chlorogenic acid = 1: 1 to 1: 200 in weight ratio range It is. Further, it is preferable to contain isothiocyanates: cocoa polyphenol = 10: 1 to 1: 2000 in weight ratio, and more preferably, a range of isothiocyanates: cocoa polyphenol = 1: 40 to 1: 400 in weight ratio It is. Moreover, it is preferable to contain it by the weight ratio of isothiocyanates: haccho miso = 1: 10-1: 50000, More preferably, the range of the weight ratio of isothiocyanates: haccho miso = 1: 600-1: 6000 It is. That is, when both are contained in such a proportion, the synergistic effect of both can effectively obtain the calcitonin gene-related peptide production and release promoting action required in the present invention. In addition, isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol, and Haccho miso can be used in combination within the above range.
The edible composition of the present invention is expected to have the same action and effect as the above-mentioned action and effect seen when administered to humans not only in humans but also in animals such as pets and livestock. And, depending on conditions such as the sex, weight, age, etc. of the person to be administered, the dose differs depending on the difference between the organisms to be administered and which one of the various effects described above is to be obtained. It is set appropriately. For example, for an adult, the mixture of the above isoflavones etc. and isothiocyanates can be divided into several doses so as to be 10 to 5000 mg per day. In addition, in animals such as pets and livestock, it is preferable that the above-mentioned mixture is contained in the animal feed in the range of 0.001 to 5%, and is administered in the range of 1 to 5000 mg / kg body weight per day.
The composition of the present invention can be taken alone, but can also be used by being added to various food products or medicines. Specifically, liquid foods such as soft drinks, tea beverages, drinks, alcoholic beverages, solid foods such as fruits, breads, noodles, seasonings, etc., pharmaceuticals such as powders, granules, capsules and tablets Add to quasi-drugs etc.
The composition of the present invention can also obtain the same effect as taking it orally or applying it by sniffing the isothiocyanate contained or exposing it to volatilized isothiocyanates. . Specifically, it can be used by blending it into an aroma oil, a fragrance, daily necessities for perfume, cosmetics, perfumes, fibers or resins, etc. and volatilizing the components.
In the present invention, when exposed to volatilized isothiocyanate, the concentration is not limited, but it is desirable that the concentration is within the range that can be recognized by human being without causing irritation or discomfort. There is no particular relationship between the concentration and the effect.
In the present invention, when it is added to aromatic oils, fragrances, daily necessities such as perfumes, cosmetics, perfumes, fibers or resins, etc. and volatilized isothiocyanates, aroma components, perfumes, etc. It can be chosen freely and does not adversely affect its effect. It can be used by blending it into a flavor that is easy to use.
Hereinafter, the present invention will be specifically described by way of examples.
〔試験例1〕イソチオシアネート類投与によるマウス各臓器のIGF−1、CGRP濃度変化
16群にわけた6−8週齢のC57BL/6マウス(雄、各群5匹)に対し、標準食にくわえ試験品を投与した。4週間投与後、麻酔下に採取した各種臓器は1Nの酢酸溶液につけてホモジネートし、遠心分離後上清中のIGF−1濃度を測定した。また、血液も採取して、血漿中のIGF−1濃度およびCGRP濃度を測定した。マウスの脳および血漿中IGF−1、CGRP濃度を表1に示した。イソチオシアネート類は、実施例においては6−メチルスルフィニルヘキシルイソチオシアネート(以下、6−MSITCと略す)を利用した。
ここで、上記16群は、投与した飼料等から、6−MSITC(MS)投与群、イソフラボン(IS)投与群、6−MSITC+イソフラボン(MS+IS)投与群、ラズベリーケトン(RA)投与群、6−MSITC+ラズベリーケトン(MS+RA)投与群、カプシエイト(CE)投与群、6−MSITC+カプシエイト(MS+CE)投与群、グルコン酸(GA)投与群、6−MSITC+グルコン酸(MS+GA)投与群、クロロゲン酸(CA)投与群、6−MSITC+クロロゲン酸(MS+CA)投与群、カカオポリフェノール(CP)投与群、6−MSITC+カカオポリフェノール(MS+CP)投与群、八丁味噌(HM)投与群、6−MSITC+八丁味噌(MS+HM)投与群、非投与群(標準食のみ。対照群)のいずれかに属する。
すなわち、各群は標準食に加え、MS投与群では、6−MSITCを0.1mg/kg/day投与。IS投与群では、イソフラボンを50mg/kg/day投与。RA投与群では、ラズベリーケトンを400mg/kg/day投与。CE投与群では、カプシエイトを0.1mg/kgの投与。GA投与群では、グルコン酸を1mg/kg/day投与。CA投与群では、クロロゲン酸を1mg/kg/day投与。CP投与群では、カカオポリフェノールを50mg/kg/day投与。HM投与群では、八丁味噌を600mg/kg/day投与。さらに、これらの組み合わせにより、MS+IS投与群、MS+RA投与群、MS+CE投与群、MS+GA投与群、MS+CA投与群、MS+CP投与群、MS+HM投与群の飼育を行った。
この結果より、6−MSITCを摂取することによりIGF−1とCGRPの分泌が促進することが示され、さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。
Test Example 1 Changes in IGF-1 and CGRP Concentrations in Mice by Administration of Isothiocyanates A standard diet was prepared for C57BL / 6 mice (male, 5 mice in each group) of 6-8 weeks divided into 16 groups. A test product was administered. After administration for 4 weeks, various organs collected under anesthesia were immersed in 1 N acetic acid solution, homogenized, and centrifuged to measure IGF-1 concentration in the supernatant. Blood was also collected to measure plasma IGF-1 and CGRP concentrations. The concentrations of IGF-1 and CGRP in mouse brain and plasma are shown in Table 1. The isothiocyanates utilized 6-methylsulfinyl hexyl isothiocyanate (hereinafter abbreviated as 6-MSITC) in the examples.
Here, the above 16 groups are administered 6-MSITC (MS), isoflavone (IS), 6-MSITC + isoflavone (MS + IS) administered, raspberry ketone (RA) administered, 6-MSITC Raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + gluconic acid (MS + GA) administration group, chlorogenic acid (CA) administration group 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) administration group, 6-MSITC + Haccho miso (MS + HM) administration group Any of non-administration group (standard diet only, control group) Or to belong.
That is, each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day. In the IS administration group, 50 mg / kg / day of isoflavone was administered. In the RA administration group, 400 mg / kg / day of raspberry ketone was administered. In the CE administration group, administration of 0.1 mg / kg of capsiate. In the GA administration group, gluconic acid was administered at 1 mg / kg / day. In the CA administration group, chlorogenic acid was administered at 1 mg / kg / day. In the CP administration group, 50 mg / kg / day of cocoa polyphenol was administered. In the HM administration group, Haccho Miso was administered at 600 mg / kg / day. Furthermore, the combination of MS + IS, MS + RA, MS + CE, MS + GA, MS + CA, MS + CP, and MS + HM was performed using these combinations.
The results show that intake of 6-MSITC promotes secretion of IGF-1 and CGRP, and further, at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols and haccho miso It was confirmed that the combined use of 6-MSITC intensified its action.
16群にわけた6−8週齢のC57BL/6マウス(雄、各群5匹)に対し、標準食にくわえ試験品を投与した。4週間投与後、麻酔下に採取した各種臓器は1Nの酢酸溶液につけてホモジネートし、遠心分離後上清中のIGF−1濃度を測定した。また、血液も採取して、血漿中のIGF−1濃度およびCGRP濃度を測定した。マウスの脳および血漿中IGF−1、CGRP濃度を表1に示した。イソチオシアネート類は、実施例においては6−メチルスルフィニルヘキシルイソチオシアネート(以下、6−MSITCと略す)を利用した。
ここで、上記16群は、投与した飼料等から、6−MSITC(MS)投与群、イソフラボン(IS)投与群、6−MSITC+イソフラボン(MS+IS)投与群、ラズベリーケトン(RA)投与群、6−MSITC+ラズベリーケトン(MS+RA)投与群、カプシエイト(CE)投与群、6−MSITC+カプシエイト(MS+CE)投与群、グルコン酸(GA)投与群、6−MSITC+グルコン酸(MS+GA)投与群、クロロゲン酸(CA)投与群、6−MSITC+クロロゲン酸(MS+CA)投与群、カカオポリフェノール(CP)投与群、6−MSITC+カカオポリフェノール(MS+CP)投与群、八丁味噌(HM)投与群、6−MSITC+八丁味噌(MS+HM)投与群、非投与群(標準食のみ。対照群)のいずれかに属する。
すなわち、各群は標準食に加え、MS投与群では、6−MSITCを0.1mg/kg/day投与。IS投与群では、イソフラボンを50mg/kg/day投与。RA投与群では、ラズベリーケトンを400mg/kg/day投与。CE投与群では、カプシエイトを0.1mg/kgの投与。GA投与群では、グルコン酸を1mg/kg/day投与。CA投与群では、クロロゲン酸を1mg/kg/day投与。CP投与群では、カカオポリフェノールを50mg/kg/day投与。HM投与群では、八丁味噌を600mg/kg/day投与。さらに、これらの組み合わせにより、MS+IS投与群、MS+RA投与群、MS+CE投与群、MS+GA投与群、MS+CA投与群、MS+CP投与群、MS+HM投与群の飼育を行った。
Here, the above 16 groups are administered 6-MSITC (MS), isoflavone (IS), 6-MSITC + isoflavone (MS + IS) administered, raspberry ketone (RA) administered, 6-MSITC Raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + gluconic acid (MS + GA) administration group, chlorogenic acid (CA) administration group 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) administration group, 6-MSITC + Haccho miso (MS + HM) administration group Any of non-administration group (standard diet only, control group) Or to belong.
That is, each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day. In the IS administration group, 50 mg / kg / day of isoflavone was administered. In the RA administration group, 400 mg / kg / day of raspberry ketone was administered. In the CE administration group, administration of 0.1 mg / kg of capsiate. In the GA administration group, gluconic acid was administered at 1 mg / kg / day. In the CA administration group, chlorogenic acid was administered at 1 mg / kg / day. In the CP administration group, 50 mg / kg / day of cocoa polyphenol was administered. In the HM administration group, Haccho Miso was administered at 600 mg / kg / day. Furthermore, the combination of MS + IS, MS + RA, MS + CE, MS + GA, MS + CA, MS + CP, and MS + HM was performed using these combinations.
〔試験例2〕イソチオシアネート類による学習機能の向上作用
16群にわけたマウス(各群5匹)に対し、4週間標準食に加え試験品を投与したのち、モーリス水迷路試験を5日間行い、学習機能に対する影響を評価した。
ここで、上記16群は、投与した飼料等から、6−MSITC(MS)投与群、イソフラボン(IS)投与群、6−MSITC+イソフラボン(MS+IS)投与群、ラズベリーケトン(RA)投与群、6−MSITC+ラズベリーケトン(MS+RA)投与群、カプシエイト(CE)投与群、6−MSITC+カプシエイト(MS+CE)投与群、グルコン酸(GA)投与群、6−MSITC+グルコン酸(MS+GA)投与群、クロロゲン酸(CA)投与群、6−MSITC+クロロゲン酸(MS+CA)投与群、カカオポリフェノール(CP)投与群、6−MSITC+カカオポリフェノール(MS+CP)投与群、八丁味噌(HM)投与群、6−MSITC+八丁味噌(MS+HM)投与群、非投与群(標準食のみ。対照群)のいずれかに属する。
すなわち、各群は標準食に加え、MS投与群では、6−MSITCを0.1mg/kg/day投与。IS投与群では、イソフラボンを50mg/kg/day投与。RA投与群では、ラズベリーケトンを400mg/kg/day投与。CE投与群では、カプシエイトを0.1mg/kg投与。GA投与群では、グルコン酸を1mg/kg/day投与。CA投与群では、クロロゲン酸を1mg/kg/day投与。CP投与群では、カカオポリフェノール50mg/kg/day投与。HM投与群では、八丁味噌を600mg/kg/day投与。さらに、これらの組み合わせにより、MS+IS投与群、MS+RA投与群、MS+CE投与群、MS+GA投与群、MS+CA投与群、MS+CP投与群、MS+HM投与群の飼育を行った。プラットホームに到達するまでの時間を表2に示した。
この結果より、6−MSITC摂取することにより、学習機能が向上することが確認され、さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。
[Test Example 2] The effect of improving learning function by isothiocyanates For the mice divided into 16 groups (5 mice in each group), in addition to the standard diet for 4 weeks a test product is administered, and then the Morris water maze test is carried out for 5 days And assessed the impact on the learning function.
Here, the above 16 groups are administered 6-MSITC (MS), isoflavone (IS), 6-MSITC + isoflavone (MS + IS) administered, raspberry ketone (RA) administered, 6-MSITC Raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + gluconic acid (MS + GA) administration group, chlorogenic acid (CA) administration group 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) administration group, 6-MSITC + Haccho miso (MS + HM) administration group Any of the non-administration group (standard diet only, control group) Or to belong.
That is, each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day. In the IS administration group, 50 mg / kg / day of isoflavone was administered. In the RA administration group, 400 mg / kg / day of raspberry ketone was administered. In the CE administration group, 0.1 mg / kg of capsiate was administered. In the GA administration group, gluconic acid was administered at 1 mg / kg / day. In the CA administration group, chlorogenic acid was administered at 1 mg / kg / day. In the CP administration group, cocoa polyphenol 50 mg / kg / day was administered. In the HM administration group, Haccho Miso was administered at 600 mg / kg / day. Furthermore, the combination of MS + IS, MS + RA, MS + CE, MS + GA, MS + CA, MS + CP, and MS + HM was performed using these combinations. The time to reach the platform is shown in Table 2.
From this result, it is confirmed that intake of 6-MSITC improves learning function, and further, at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol, and hachicho-miso and 6-MSITC It was confirmed that the combined use intensified the action.
16群にわけたマウス(各群5匹)に対し、4週間標準食に加え試験品を投与したのち、モーリス水迷路試験を5日間行い、学習機能に対する影響を評価した。
ここで、上記16群は、投与した飼料等から、6−MSITC(MS)投与群、イソフラボン(IS)投与群、6−MSITC+イソフラボン(MS+IS)投与群、ラズベリーケトン(RA)投与群、6−MSITC+ラズベリーケトン(MS+RA)投与群、カプシエイト(CE)投与群、6−MSITC+カプシエイト(MS+CE)投与群、グルコン酸(GA)投与群、6−MSITC+グルコン酸(MS+GA)投与群、クロロゲン酸(CA)投与群、6−MSITC+クロロゲン酸(MS+CA)投与群、カカオポリフェノール(CP)投与群、6−MSITC+カカオポリフェノール(MS+CP)投与群、八丁味噌(HM)投与群、6−MSITC+八丁味噌(MS+HM)投与群、非投与群(標準食のみ。対照群)のいずれかに属する。
すなわち、各群は標準食に加え、MS投与群では、6−MSITCを0.1mg/kg/day投与。IS投与群では、イソフラボンを50mg/kg/day投与。RA投与群では、ラズベリーケトンを400mg/kg/day投与。CE投与群では、カプシエイトを0.1mg/kg投与。GA投与群では、グルコン酸を1mg/kg/day投与。CA投与群では、クロロゲン酸を1mg/kg/day投与。CP投与群では、カカオポリフェノール50mg/kg/day投与。HM投与群では、八丁味噌を600mg/kg/day投与。さらに、これらの組み合わせにより、MS+IS投与群、MS+RA投与群、MS+CE投与群、MS+GA投与群、MS+CA投与群、MS+CP投与群、MS+HM投与群の飼育を行った。プラットホームに到達するまでの時間を表2に示した。
Here, the above 16 groups are administered 6-MSITC (MS), isoflavone (IS), 6-MSITC + isoflavone (MS + IS) administered, raspberry ketone (RA) administered, 6-MSITC Raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + gluconic acid (MS + GA) administration group, chlorogenic acid (CA) administration group 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) administration group, 6-MSITC + Haccho miso (MS + HM) administration group Any of the non-administration group (standard diet only, control group) Or to belong.
That is, each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day. In the IS administration group, 50 mg / kg / day of isoflavone was administered. In the RA administration group, 400 mg / kg / day of raspberry ketone was administered. In the CE administration group, 0.1 mg / kg of capsiate was administered. In the GA administration group, gluconic acid was administered at 1 mg / kg / day. In the CA administration group, chlorogenic acid was administered at 1 mg / kg / day. In the CP administration group, cocoa polyphenol 50 mg / kg / day was administered. In the HM administration group, Haccho Miso was administered at 600 mg / kg / day. Furthermore, the combination of MS + IS, MS + RA, MS + CE, MS + GA, MS + CA, MS + CP, and MS + HM was performed using these combinations. The time to reach the platform is shown in Table 2.
〔試験例3〕6−MSITC投与によるマウス脳における神経再生効果の検定
実施例2終了後、実験に使用したマウスの脳を採取し、神経再生に対する影響を評価した。その際、5−bromo−2−deoxyuridine(Brdu)およびBrdu抗体を用いることにより、新生した神経細胞を検出した。
左右の海馬神経細胞層長および神経細胞数を計測し、単位長さ(mm)当たりの個数を算出することによって、組織学的評価を行った。その結果、MS投与群は対照群と比較して有意に新生細胞数が増加していた。またMSと他の試験物質を組み合わせて投与した群ではさらに顕著な増加傾向を示した。例えば、対照群では2.4±0.8個/mmであったのに対し、MS投与群では5.8±1.1個/mmであり、MS+IS投与群では6.7±1.3個/mmであった。
この結果より、6−MSITC摂取することにより、神経細胞が再生されることが確認され、さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。 Test Example 3 Test of nerve regeneration effect in mouse brain by 6-MSITC administration After Example 2, the brains of mice used in the experiment were collected, and the influence on nerve regeneration was evaluated. At that time, newborn neurons were detected by using 5-bromo-2-deoxyuridine (Brdu) and Brdu antibodies.
Histological evaluation was performed by measuring left and right hippocampal neuronal layer length and neuronal cell number and calculating the number per unit length (mm). As a result, the number of neoplastic cells was significantly increased in the MS administration group as compared to the control group. In addition, in the group administered in combination with MS and other test substances, the tendency to increase was more remarkable. For example, in the control group, it was 2.4 ± 0.8, whereas in the MS administration group it was 5.8 ± 1.1, in the MS + IS administration group it was 6.7 ± 1.3. It was piece / mm.
From this result, it is confirmed that the nerve cells are regenerated by taking 6-MSITC, and further, a combination of 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid chlorogenic acid, cocoa polyphenol and hacho-miso Was confirmed to intensify its action.
実施例2終了後、実験に使用したマウスの脳を採取し、神経再生に対する影響を評価した。その際、5−bromo−2−deoxyuridine(Brdu)およびBrdu抗体を用いることにより、新生した神経細胞を検出した。
左右の海馬神経細胞層長および神経細胞数を計測し、単位長さ(mm)当たりの個数を算出することによって、組織学的評価を行った。その結果、MS投与群は対照群と比較して有意に新生細胞数が増加していた。またMSと他の試験物質を組み合わせて投与した群ではさらに顕著な増加傾向を示した。例えば、対照群では2.4±0.8個/mmであったのに対し、MS投与群では5.8±1.1個/mmであり、MS+IS投与群では6.7±1.3個/mmであった。
この結果より、6−MSITC摂取することにより、神経細胞が再生されることが確認され、さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。 Test Example 3 Test of nerve regeneration effect in mouse brain by 6-MSITC administration After Example 2, the brains of mice used in the experiment were collected, and the influence on nerve regeneration was evaluated. At that time, newborn neurons were detected by using 5-bromo-2-deoxyuridine (Brdu) and Brdu antibodies.
Histological evaluation was performed by measuring left and right hippocampal neuronal layer length and neuronal cell number and calculating the number per unit length (mm). As a result, the number of neoplastic cells was significantly increased in the MS administration group as compared to the control group. In addition, in the group administered in combination with MS and other test substances, the tendency to increase was more remarkable. For example, in the control group, it was 2.4 ± 0.8, whereas in the MS administration group it was 5.8 ± 1.1, in the MS + IS administration group it was 6.7 ± 1.3. It was piece / mm.
From this result, it is confirmed that the nerve cells are regenerated by taking 6-MSITC, and further, a combination of 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid chlorogenic acid, cocoa polyphenol and hacho-miso Was confirmed to intensify its action.
〔試験例4〕6−MSITC投与による抗うつ作用の評価
実施例2と同様に16群にわけ、標準食、各試験試料を投与したマウスにおける抗うつ作用への影響をテールサスペンション実験により検討した。体重20−25g、8週齢の雄マウスを使用した。高さ60cmのスタンドに床から35cmの高さで固定した木製クリップにより、マウスの尻尾をはさみ、逆さ吊りした。マウスは最初激しく活動するが、次第に動くことを諦める。サスペンション開始後6分以内の動いていない時間(無働時間)の短縮として、投与した成分の抗うつ効果を評価した。
その結果、MS投与群では、対照群と比較して無働時間は有意に30%短縮していた。さらにMSと他の素材を組み合わせて投与した各群では対照群と比較して35%から40%にまで短縮していた。この結果より、6−MSITC摂取することによる、抗うつ効果が示され、さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。 [Test Example 4] Evaluation of antidepressant action by 6-MSITC administration As in Example 2, divided into 16 groups, the effect on the antidepressant action in mice receiving the standard diet and each test sample was examined by tail suspension test . Male mice weighing 20-25 g and 8 weeks old were used. The tail of the mouse was pinched and hung upside down with a wooden clip fixed at a height of 35 cm from the floor on a stand 60 cm high. The mouse is active at first, but gives up gradually to move. The antidepressant effect of the administered ingredients was evaluated as shortening of the non-moving time (inactive time) within 6 minutes after the start of suspension.
As a result, in the MS administration group, the inactive time was significantly reduced by 30% as compared with the control group. Furthermore, in each group which received combining MS and other materials, it was shortened from 35% to 40% compared with the control group. The results show that the antidepressant effect is obtained by taking 6-MSITC, and the action is also obtained by combining 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols and haccho miso. Was confirmed to strengthen.
実施例2と同様に16群にわけ、標準食、各試験試料を投与したマウスにおける抗うつ作用への影響をテールサスペンション実験により検討した。体重20−25g、8週齢の雄マウスを使用した。高さ60cmのスタンドに床から35cmの高さで固定した木製クリップにより、マウスの尻尾をはさみ、逆さ吊りした。マウスは最初激しく活動するが、次第に動くことを諦める。サスペンション開始後6分以内の動いていない時間(無働時間)の短縮として、投与した成分の抗うつ効果を評価した。
その結果、MS投与群では、対照群と比較して無働時間は有意に30%短縮していた。さらにMSと他の素材を組み合わせて投与した各群では対照群と比較して35%から40%にまで短縮していた。この結果より、6−MSITC摂取することによる、抗うつ効果が示され、さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。 [Test Example 4] Evaluation of antidepressant action by 6-MSITC administration As in Example 2, divided into 16 groups, the effect on the antidepressant action in mice receiving the standard diet and each test sample was examined by tail suspension test . Male mice weighing 20-25 g and 8 weeks old were used. The tail of the mouse was pinched and hung upside down with a wooden clip fixed at a height of 35 cm from the floor on a stand 60 cm high. The mouse is active at first, but gives up gradually to move. The antidepressant effect of the administered ingredients was evaluated as shortening of the non-moving time (inactive time) within 6 minutes after the start of suspension.
As a result, in the MS administration group, the inactive time was significantly reduced by 30% as compared with the control group. Furthermore, in each group which received combining MS and other materials, it was shortened from 35% to 40% compared with the control group. The results show that the antidepressant effect is obtained by taking 6-MSITC, and the action is also obtained by combining 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols and haccho miso. Was confirmed to strengthen.
〔試験例5〕卵巣摘出ラットにおける6−MSITCによるカルシトニン遺伝子関連ペプチドの産生促進作用と骨粗鬆症に対する効果の検定
17群に分けた80日齢のSD系雌ラット(1群あたり5匹。なお、上記21群の20群は、卵巣摘出がなされた、摘出後10日目のラット)に標準食〔カルシウム欠乏飼料(Ca:0.004%、P:0.3%)〕等を投与して、28日間飼育した。その後、1晩(18時間)絶食させ、全群のラットを屠殺し、そこから大腿骨を摘出した。
卵巣を摘出した16群には、後記の表3に示すように、上記絶食前に投与した飼料等から、6−MSITC(MS)投与群、イソフラボン(IS)投与群、6−MSITC+イソフラボン(MS+IS)投与群、ラズベリーケトン(RA)投与群、6−MSITC+ラズベリーケトン(MS+RA)投与群、カプシエイト(CE)投与群、6−MSITC+カプシエイト(MS+CE)投与群、グルコン酸(GA)投与群、6−MSITC+グルコン酸(MS+GA)投与群、クロロゲン酸(CA)投与群、6−MSITC+クロロゲン酸(MS+CA)投与群、カカオポリフェノール(CP)投与群、6−MSITC+カカオポリフェノール(MS+CP)投与群、八丁味噌(HM)投与群、6−MSITC+八丁味噌(MS+HM)投与群、非投与群(標準食のみ。対照群)のいずれかに属する。
すなわち、各群は標準食に加え、MS投与群では、6−MSITCを0.1mg/kg/day投与。IS投与群では、イソフラボンを50mg/kg/day投与。RA投与群では、ラズベリーケトン400mg/kg/day投与。CE投与群では、カプシエイトを0.1mg/kg投与。GA投与群では、グルコン酸を1mg/kg/day投与。CA投与群では、クロロゲン酸1mg/kg/day投与。CP投与群では、カカオポリフェノールを50mg/kg/day投与。HM投与群では、八丁味噌を600mg/kg/day投与。さらに、これらの組み合わせにより、MS+IS投与群、MS+RA投与群、MS+CE投与群、MS+GA投与群、MS+CA投与群、MS+CP投与群、MS+HM投与群の飼育を行った。
そして、上記17群、すなわち、正常群(卵巣摘出なし)と対照群(卵巣摘出)と15の試験群(卵巣摘出+6−MSITC等の投与)から摘出された大腿骨をもとに、その湿重量を測定するとともに、ピクノメーターによりその体積を測定し、骨密度を算出した。また、骨組織のカルシトニン遺伝子関連ペプチド濃度(CGRP)の測定も行った。これらの結果を、下記の表3に併せて示す。なお、各データは、それぞれの群での平均値を示すものである。
上記表3の結果より、6−MSITCを摂取することは、カルシトニン遺伝子関連ペプチドの産生および放出を促進し、骨粗鬆症を予防および治療しうること、さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。
Test Example 5 Test of action to promote calcitonin gene related peptide production by 6-MSITC in ovariectomized rats and effect on osteoporosis 80 SD female rats (5 rats per group, divided into 17 groups) Twenty groups of 21 groups were given an ovariectomized rat on day 10 after excision and a standard diet [Ca-deficient diet (Ca: 0.004%, P: 0.3%)] etc. I kept it for 28 days. Thereafter, they were fasted overnight (18 hours), and rats in all groups were sacrificed and femurs were removed therefrom.
As shown in Table 3 below, the 16 groups from which the ovaries were removed were, for example, the 6-MSITC (MS) administration group, the isoflavone (IS) administration group, 6-MSITC + isoflavone (MS + IS IS Administration group, raspberry ketone (RA) administration group, 6-MSITC + raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + glucone Acid (MS + GA) administration group, chlorogenic acid (CA) administration group, 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) Administration group, 6-MSITC + Haccho miso (MS + HM) administration , It belongs to one of the non-administered group (standard diet only. Control group).
That is, each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day. In the IS administration group, 50 mg / kg / day of isoflavone was administered. In the RA administration group, raspberry ketone 400 mg / kg / day was administered. In the CE administration group, 0.1 mg / kg of capsiate was administered. In the GA administration group, gluconic acid was administered at 1 mg / kg / day. In the CA administration group, chlorogenic acid 1 mg / kg / day was administered. In the CP administration group, 50 mg / kg / day of cocoa polyphenol was administered. In the HM administration group, Haccho Miso was administered at 600 mg / kg / day. Furthermore, the combination of MS + IS, MS + RA, MS + CE, MS + GA, MS + CA, MS + CP, and MS + HM was performed using these combinations.
Then, based on the femur removed from the 17 groups described above, that is, the normal group (without ovariectomy) and the control group (ovariectomy) and 15 test groups (administration of ovariectomy + 6-MSITC etc.) The weight was measured and the volume was measured by a pycnometer to calculate bone density. In addition, measurement of calcitonin gene related peptide concentration (CGRP) in bone tissue was also performed. These results are shown together in Table 3 below. Each data shows the average value in each group.
From the results of Table 3, it can be seen that intake of 6-MSITC promotes production and release of calcitonin gene-related peptide, and can prevent and treat osteoporosis, and isoflavones, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, It has been confirmed that the action is enhanced by the combination of 6-MSITC with at least one of cocoa polyphenol and hacho-miso.
17群に分けた80日齢のSD系雌ラット(1群あたり5匹。なお、上記21群の20群は、卵巣摘出がなされた、摘出後10日目のラット)に標準食〔カルシウム欠乏飼料(Ca:0.004%、P:0.3%)〕等を投与して、28日間飼育した。その後、1晩(18時間)絶食させ、全群のラットを屠殺し、そこから大腿骨を摘出した。
卵巣を摘出した16群には、後記の表3に示すように、上記絶食前に投与した飼料等から、6−MSITC(MS)投与群、イソフラボン(IS)投与群、6−MSITC+イソフラボン(MS+IS)投与群、ラズベリーケトン(RA)投与群、6−MSITC+ラズベリーケトン(MS+RA)投与群、カプシエイト(CE)投与群、6−MSITC+カプシエイト(MS+CE)投与群、グルコン酸(GA)投与群、6−MSITC+グルコン酸(MS+GA)投与群、クロロゲン酸(CA)投与群、6−MSITC+クロロゲン酸(MS+CA)投与群、カカオポリフェノール(CP)投与群、6−MSITC+カカオポリフェノール(MS+CP)投与群、八丁味噌(HM)投与群、6−MSITC+八丁味噌(MS+HM)投与群、非投与群(標準食のみ。対照群)のいずれかに属する。
すなわち、各群は標準食に加え、MS投与群では、6−MSITCを0.1mg/kg/day投与。IS投与群では、イソフラボンを50mg/kg/day投与。RA投与群では、ラズベリーケトン400mg/kg/day投与。CE投与群では、カプシエイトを0.1mg/kg投与。GA投与群では、グルコン酸を1mg/kg/day投与。CA投与群では、クロロゲン酸1mg/kg/day投与。CP投与群では、カカオポリフェノールを50mg/kg/day投与。HM投与群では、八丁味噌を600mg/kg/day投与。さらに、これらの組み合わせにより、MS+IS投与群、MS+RA投与群、MS+CE投与群、MS+GA投与群、MS+CA投与群、MS+CP投与群、MS+HM投与群の飼育を行った。
そして、上記17群、すなわち、正常群(卵巣摘出なし)と対照群(卵巣摘出)と15の試験群(卵巣摘出+6−MSITC等の投与)から摘出された大腿骨をもとに、その湿重量を測定するとともに、ピクノメーターによりその体積を測定し、骨密度を算出した。また、骨組織のカルシトニン遺伝子関連ペプチド濃度(CGRP)の測定も行った。これらの結果を、下記の表3に併せて示す。なお、各データは、それぞれの群での平均値を示すものである。
As shown in Table 3 below, the 16 groups from which the ovaries were removed were, for example, the 6-MSITC (MS) administration group, the isoflavone (IS) administration group, 6-MSITC + isoflavone (MS + IS IS Administration group, raspberry ketone (RA) administration group, 6-MSITC + raspberry ketone (MS + RA) administration group, capsiate (CE) administration group, 6-MSITC + capsiate (MS + CE) administration group, gluconic acid (GA) administration group, 6-MSITC + glucone Acid (MS + GA) administration group, chlorogenic acid (CA) administration group, 6-MSITC + chlorogenic acid (MS + CA) administration group, cocoa polyphenol (CP) administration group, 6-MSITC + cocoa polyphenol (MS + CP) administration group, Haccho miso (HM) Administration group, 6-MSITC + Haccho miso (MS + HM) administration , It belongs to one of the non-administered group (standard diet only. Control group).
That is, each group is added to the standard diet, and in the MS administration group, 6-MSITC is administered at 0.1 mg / kg / day. In the IS administration group, 50 mg / kg / day of isoflavone was administered. In the RA administration group, raspberry ketone 400 mg / kg / day was administered. In the CE administration group, 0.1 mg / kg of capsiate was administered. In the GA administration group, gluconic acid was administered at 1 mg / kg / day. In the CA administration group, chlorogenic acid 1 mg / kg / day was administered. In the CP administration group, 50 mg / kg / day of cocoa polyphenol was administered. In the HM administration group, Haccho Miso was administered at 600 mg / kg / day. Furthermore, the combination of MS + IS, MS + RA, MS + CE, MS + GA, MS + CA, MS + CP, and MS + HM was performed using these combinations.
Then, based on the femur removed from the 17 groups described above, that is, the normal group (without ovariectomy) and the control group (ovariectomy) and 15 test groups (administration of ovariectomy + 6-MSITC etc.) The weight was measured and the volume was measured by a pycnometer to calculate bone density. In addition, measurement of calcitonin gene related peptide concentration (CGRP) in bone tissue was also performed. These results are shown together in Table 3 below. Each data shows the average value in each group.
〔試験例6〕脳卒中易発症高血圧自然発症ラット(SHR−SP)における6−MSITC投与によるカルシトニン遺伝子関連ペプチドの産生促進作用と高血圧に対する効果の検定
18周齢の雄性SHRSP/1zmラットを、実施例2と同様に、1グループ5匹の16グループにわけ、グループ1から15には標準食に加え各試験試料を投与グループ16は対照群とした。
そして、投与50日目の尾部血圧測定を行った。その結果、MS投与群(248±6.3mmHg)では対照群(281±5.2mmHg)に比べ有意に血圧が低下していた。さらにMS+各試験食を組み合わせた群では、より顕著な血圧低下傾向を示した。
上記の結果より、6−MSITCを摂取することは、カルシトニン遺伝子関連ペプチドの産生および放出を促進すれため、高血圧に対して効果があることがわかる。さらに、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。 [Test Example 6] Test for promoting production of calcitonin gene-related peptide by administration of 6-MSITC and effect on hypertension in stroke-prone spontaneously hypertensive rats (SHR-SP) Test of 18-week-old male SHRSP / 1zm rat As in 2, the group was divided into 16 groups of 5 animals, and each of the test samples served as a control group in addition to the standard diet in groups 1 to 15.
Then, tail blood pressure was measured on the 50th day of administration. As a result, in the MS administration group (248 ± 6.3 mmHg), the blood pressure was significantly lowered compared to the control group (281 ± 5.2 mmHg). Furthermore, in the group which combined MS + each test diet, the blood pressure lowering tendency was more pronounced.
From the above results, it can be seen that intake of 6-MSITC has an effect on hypertension since it promotes production and release of calcitonin gene-related peptide. Furthermore, it has been confirmed that the action is enhanced by the combination of 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol and Haccho miso.
18周齢の雄性SHRSP/1zmラットを、実施例2と同様に、1グループ5匹の16グループにわけ、グループ1から15には標準食に加え各試験試料を投与グループ16は対照群とした。
そして、投与50日目の尾部血圧測定を行った。その結果、MS投与群(248±6.3mmHg)では対照群(281±5.2mmHg)に比べ有意に血圧が低下していた。さらにMS+各試験食を組み合わせた群では、より顕著な血圧低下傾向を示した。
上記の結果より、6−MSITCを摂取することは、カルシトニン遺伝子関連ペプチドの産生および放出を促進すれため、高血圧に対して効果があることがわかる。さらに、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。 [Test Example 6] Test for promoting production of calcitonin gene-related peptide by administration of 6-MSITC and effect on hypertension in stroke-prone spontaneously hypertensive rats (SHR-SP) Test of 18-week-old male SHRSP / 1zm rat As in 2, the group was divided into 16 groups of 5 animals, and each of the test samples served as a control group in addition to the standard diet in groups 1 to 15.
Then, tail blood pressure was measured on the 50th day of administration. As a result, in the MS administration group (248 ± 6.3 mmHg), the blood pressure was significantly lowered compared to the control group (281 ± 5.2 mmHg). Furthermore, in the group which combined MS + each test diet, the blood pressure lowering tendency was more pronounced.
From the above results, it can be seen that intake of 6-MSITC has an effect on hypertension since it promotes production and release of calcitonin gene-related peptide. Furthermore, it has been confirmed that the action is enhanced by the combination of 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol and Haccho miso.
〔試験例7〕イソフラボンとカプサイシンによる毛包中のカルシトニン遺伝子関連ペプチドおよびインスリン様成長因子の産生促進作用と育毛効果の検定
3周齢で購入したC3H/He系マウスを、ランダムに1グループ10匹とし16グループに分け、1週間の馴化飼育後、グループ1は、6−MSITCの摂取量が0.1mg/kg体重/dayとなるように調製した飼料で飼育した。グループ2は、イソフラボン(IS)の摂取量が40mg/kg体重/dayとなるように調製した飼料で飼育した。グループ4では、ラズベリーケトン(RA)の摂取量が600mg/kg体重/dayとなるように調製した飼料で飼育した。グループ6では、カプシエイト(CE)の摂取量が1mg/kg体重/dayとなるように調製した飼料で飼育した。グループ8では、グルコン酸(GA)の摂取量が4mg/kg体重/dayとなるように調製した飼料で飼育した。グループ10では、クロロゲン酸(CA)の摂取量が3mg/kg体重/dayとなるように調製した飼料で飼育した。グループ12では、カカオポリフェノール(CP)の摂取量が200mg/kg体重/dayとなるように調製した飼料で飼育した。グループ14では、八丁味噌(HM)の摂取量が600mg/kg体重/dayとなるように調製した飼料で飼育した。また、グループ3、5、7、9、11、13、15では、これら飼育方法の組み合わせ(下記の表4に示す組み合わせ)により、飼育した。グループ16は、対照群とした。そして、6周齢で毛刈りを行い、その後の発毛の状況を観察した。
すなわち、試験飼料の摂取開始後40日以内に毛の再生が完了したマウスの数の測定を行った。この結果を、下記の表4に示す。
上記表4の結果より、6−MSITCを育毛効果のあることが認められた。さらにイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノールおよび八丁味噌のうち少なくとも1つと6−MSITCの併用によりその作用が強まることが確かめられた。また、毛包中のカルシトニン遺伝子関連ペプチドおよびインスリン様成長因子の量を測定した結果、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌のうち少なくとも1つと6−MSITCを 同時に与えたグループが他のグループと比較して有意に多いことがわかった。
[Test Example 7] Test of production promoting action and hair growth effect of calcitonin gene-related peptide and hair growth effect in hair follicles by isoflavone and capsaicin C3H / He mice purchased at 3 weeks of age, 10 groups randomly After dividing into 16 groups and 1 week of acclimatization rearing, Group 1 was reared with a feed adjusted to have an intake of 6-MSITC of 0.1 mg / kg body weight / day. Group 2 was reared with a feed adjusted to have an intake of isoflavone (IS) of 40 mg / kg body weight / day. In group 4, the animals were reared with a feed adjusted to have an intake of raspberry ketone (RA) of 600 mg / kg body weight / day. In group 6, the animals were fed with a feed adjusted to have an intake of capsiate (CE) of 1 mg / kg body weight / day. In group 8, the animals were fed with a feed adjusted to have an intake of gluconic acid (GA) of 4 mg / kg body weight / day. In group 10, the animals were fed with a feed adjusted to have an intake of chlorogenic acid (CA) of 3 mg / kg body weight / day. In group 12, the animals were fed with a feed adjusted to have an intake of cocoa polyphenol (CP) of 200 mg / kg body weight / day. In group 14, the animals were reared with a feed adjusted to have an intake of 600 mg / kg body weight / day of Haccho Miso (HM). Moreover, in groups 3, 5, 7, 9, 11, 13, and 15, breeding was performed by a combination of these breeding methods (combination shown in Table 4 below). Group 16 was a control group. Then, she was shaved at 6 weeks of age and observed the condition of hair growth thereafter.
That is, the number of mice in which hair regeneration was completed within 40 days after the start of the intake of the test feed was measured. The results are shown in Table 4 below.
From the results of Table 4 above, it was recognized that 6-MSITC had a hair growth effect. Furthermore, it has been confirmed that the action is enhanced by the combination of 6-MSITC with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenol and Haccho miso. In addition, at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and haccho miso and 6-MSITC are simultaneously measured as a result of measuring the amount of calcitonin gene-related peptide and insulin-like growth factor in hair follicles. It was found that the given group was significantly more than the other groups.
3周齢で購入したC3H/He系マウスを、ランダムに1グループ10匹とし16グループに分け、1週間の馴化飼育後、グループ1は、6−MSITCの摂取量が0.1mg/kg体重/dayとなるように調製した飼料で飼育した。グループ2は、イソフラボン(IS)の摂取量が40mg/kg体重/dayとなるように調製した飼料で飼育した。グループ4では、ラズベリーケトン(RA)の摂取量が600mg/kg体重/dayとなるように調製した飼料で飼育した。グループ6では、カプシエイト(CE)の摂取量が1mg/kg体重/dayとなるように調製した飼料で飼育した。グループ8では、グルコン酸(GA)の摂取量が4mg/kg体重/dayとなるように調製した飼料で飼育した。グループ10では、クロロゲン酸(CA)の摂取量が3mg/kg体重/dayとなるように調製した飼料で飼育した。グループ12では、カカオポリフェノール(CP)の摂取量が200mg/kg体重/dayとなるように調製した飼料で飼育した。グループ14では、八丁味噌(HM)の摂取量が600mg/kg体重/dayとなるように調製した飼料で飼育した。また、グループ3、5、7、9、11、13、15では、これら飼育方法の組み合わせ(下記の表4に示す組み合わせ)により、飼育した。グループ16は、対照群とした。そして、6周齢で毛刈りを行い、その後の発毛の状況を観察した。
すなわち、試験飼料の摂取開始後40日以内に毛の再生が完了したマウスの数の測定を行った。この結果を、下記の表4に示す。
That is, the number of mice in which hair regeneration was completed within 40 days after the start of the intake of the test feed was measured. The results are shown in Table 4 below.
〔試験例8〕ヒトに対する育毛効果
脱毛、薄毛の悩みを持っているボランティア男性(30~50歳)を対象とし、1グループ5人の計16グループにわけた。そして、そのうちのグループ1では、6−MSITC(MS)を含む錠剤の投与により1日1mgの6−MSITCを摂取させ、グループ2では、イソフラボン(IS)を含む錠剤の投与により1日50mgのイソフラボンを摂取させた。グループ4ではラズベリーケトン(RA)を含む錠剤の投与により1日600mgのラズベリーケトンを摂取させた。グループ6ではカプシエイト(CE)を含む錠剤の投与により1日2mgのカプシエイトを摂取させた。グループ8ではグルコン酸(GA)を含む錠剤の投与により1日100mgのグルコン酸を摂取させた。グループ10ではクロロゲン酸(CA)を含む錠剤の投与により1日100mgのクロロゲン酸を摂取させた。グループ12ではカカオポリフェノール(CP)を含む錠剤の投与により1日600mgのカカオポリフェノールを摂取させた。グループ14では八調味噌(HM)を1日5000mg摂取させた。またグループ3、5、7、9、11、13、15には表5に示すようなこれらの組み合わせで摂取させた。なお、グループ16には擬似錠剤を摂取させた。これを6ヶ月にわたって行った。
次に、上記試験中(試料を摂取する前、3ヶ月摂取後、および6ヶ月摂取後)に採取しておいた抜け毛の本数を測定し、抜け毛改善効果の評価を行った。なお、上記抜け毛の測定方法は、4日間の連続洗髪を行い、後半3日間の抜け毛をメッシュの微細な不織布で採取し、その本数を計数し、行った。そして、上記評価の判定は、試料採取前に対する各々の時期における抜け毛本数の変化から次のように示した。
+++:抜け毛本数が30本以上減っており、著しい効果が認められた。
++:抜け毛本数が20本以上減っており、かなりの効果が認められた。
+:抜け毛本数が10本以上減っており、わずかな効果が認められた。
±:抜け毛本数の減少が10本未満もしくは増加しており、効果が殆ど認められなかった。
上記表5の結果より、6−MSITCを単独でまたはイソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌のうち少なくとも1つと6−MSITCを組み合わせて摂取した場合では、擬似錠剤を摂取したグループに比べ、抜け毛の改善効果が認められた。あそして、特に6−MSITCとイソフラボンまたはローヤルゼリーとを同時に摂取させたグループでは、抜け毛に対して著明な改善効果が認められた。
[Test Example 8] Hair growth effect on humans A group of five volunteers, divided into a total of 16 groups, targeted to male volunteers (30 to 50 years old) who had hair loss and thin hair problems. And in the group 1 of them, 1 mg of 6-MSITC is ingested daily by administration of a tablet containing 6-MSITC (MS), and in group 2 is 50 mg of isoflavone daily by administration of a tablet containing isoflavone (IS) I was given In group 4, 600 mg of raspberry ketone was ingested daily by administration of a tablet containing raspberry ketone (RA). In group 6, 2 mg of capsiate was taken daily by administration of a tablet containing capsiate (CE). In group 8, 100 mg of gluconic acid was ingested daily by administration of a tablet containing gluconic acid (GA). In group 10, 100 mg of chlorogenic acid was ingested daily by administration of a tablet containing chlorogenic acid (CA). In group 12, 600 mg of cocoa polyphenol was ingested daily by administration of a tablet containing cocoa polyphenol (CP). In group 14, Hachidamei (HM) was ingested 5000 mg a day. Groups 3, 5, 7, 9, 11, 13, 15 were also ingested with these combinations as shown in Table 5. Group 16 was ingested a simulated tablet. This was done for six months.
Next, the number of hair loss collected during the above test (before taking the sample, after taking three months, and after taking six months) was measured to evaluate the hair loss improving effect. In addition, the measurement method of the above-mentioned hair loss performed four days continuous hair washing, collected the hair loss of the last three days with the fine nonwoven fabric of mesh, counted the number, and was performed. And the judgment of the said evaluation was shown as follows from the change of the number of hair loss in each time with respect to sampling before.
+++: The number of hair loss has been reduced by 30 or more, and a remarkable effect was observed.
++: The number of hair loss has been reduced by more than 20, and a considerable effect was observed.
+: The number of hair loss was reduced by 10 or more, and a slight effect was observed.
±: Decrease or decrease in the number of hair loss was less than 10, and almost no effect was observed.
From the results in Table 5 above, when 6-MSITC is ingested alone or in combination with at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and Haccho miso together with 6-MSITC, a simulated tablet is obtained. Hair loss was improved compared to the group who received Also, in the group in which 6-MSITC and isoflavone or royal jelly were simultaneously ingested, a remarkable improvement effect on hair loss was observed.
脱毛、薄毛の悩みを持っているボランティア男性(30~50歳)を対象とし、1グループ5人の計16グループにわけた。そして、そのうちのグループ1では、6−MSITC(MS)を含む錠剤の投与により1日1mgの6−MSITCを摂取させ、グループ2では、イソフラボン(IS)を含む錠剤の投与により1日50mgのイソフラボンを摂取させた。グループ4ではラズベリーケトン(RA)を含む錠剤の投与により1日600mgのラズベリーケトンを摂取させた。グループ6ではカプシエイト(CE)を含む錠剤の投与により1日2mgのカプシエイトを摂取させた。グループ8ではグルコン酸(GA)を含む錠剤の投与により1日100mgのグルコン酸を摂取させた。グループ10ではクロロゲン酸(CA)を含む錠剤の投与により1日100mgのクロロゲン酸を摂取させた。グループ12ではカカオポリフェノール(CP)を含む錠剤の投与により1日600mgのカカオポリフェノールを摂取させた。グループ14では八調味噌(HM)を1日5000mg摂取させた。またグループ3、5、7、9、11、13、15には表5に示すようなこれらの組み合わせで摂取させた。なお、グループ16には擬似錠剤を摂取させた。これを6ヶ月にわたって行った。
次に、上記試験中(試料を摂取する前、3ヶ月摂取後、および6ヶ月摂取後)に採取しておいた抜け毛の本数を測定し、抜け毛改善効果の評価を行った。なお、上記抜け毛の測定方法は、4日間の連続洗髪を行い、後半3日間の抜け毛をメッシュの微細な不織布で採取し、その本数を計数し、行った。そして、上記評価の判定は、試料採取前に対する各々の時期における抜け毛本数の変化から次のように示した。
+++:抜け毛本数が30本以上減っており、著しい効果が認められた。
++:抜け毛本数が20本以上減っており、かなりの効果が認められた。
+:抜け毛本数が10本以上減っており、わずかな効果が認められた。
±:抜け毛本数の減少が10本未満もしくは増加しており、効果が殆ど認められなかった。
Next, the number of hair loss collected during the above test (before taking the sample, after taking three months, and after taking six months) was measured to evaluate the hair loss improving effect. In addition, the measurement method of the above-mentioned hair loss performed four days continuous hair washing, collected the hair loss of the last three days with the fine nonwoven fabric of mesh, counted the number, and was performed. And the judgment of the said evaluation was shown as follows from the change of the number of hair loss in each time with respect to sampling before.
+++: The number of hair loss has been reduced by 30 or more, and a remarkable effect was observed.
++: The number of hair loss has been reduced by more than 20, and a considerable effect was observed.
+: The number of hair loss was reduced by 10 or more, and a slight effect was observed.
±: Decrease or decrease in the number of hair loss was less than 10, and almost no effect was observed.
〔試験例9〕イソチオシアネートル類含有ローションによる皮膚IGF−1産生促進作用の検定
4群に分けたヘアレスマウス(各群5匹)のうち3群に対して、6−MSITC0.001%、0.01%、0.1%の各濃度を含有したローションを塗布し、30分後の表皮組織および真皮組織中のIGF−1濃度を測定した。また残りの1群をコントロール群として、6−MSITCを含まないローションを塗布して同様の測定を行った。この結果を表6に示す。
表6の結果より、6−MSITCを0.001%あるいは0.01%含有するローションの塗布により、表皮および真皮中のIGF−1濃度がコントロール群に対して有意に上昇することがわかる。
[Test Example 9] Assay of skin IGF-1 production promoting effect by lotion containing isothiocyanates 6% relative to 3 groups of 3 groups of hairless mice (5 animals in each group) divided into 4 groups A lotion containing .01% and 0.1% of each concentration was applied, and IGF-1 concentration in epidermal tissue and dermal tissue was measured after 30 minutes. Also, using the remaining one group as a control group, a lotion without 6-MSITC was applied and the same measurement was performed. The results are shown in Table 6.
From the results in Table 6, it can be seen that application of a lotion containing 0.001% or 0.01% of 6-MSITC significantly increases the IGF-1 concentration in the epidermis and dermis relative to the control group.
4群に分けたヘアレスマウス(各群5匹)のうち3群に対して、6−MSITC0.001%、0.01%、0.1%の各濃度を含有したローションを塗布し、30分後の表皮組織および真皮組織中のIGF−1濃度を測定した。また残りの1群をコントロール群として、6−MSITCを含まないローションを塗布して同様の測定を行った。この結果を表6に示す。
〔試験例10〕イソチオシアネート類含有ローション塗布によるヒトに対する育毛効果の検定
脱毛、薄毛の悩みを持っているボランティア男性(30~50歳)を対象とし、1グループ5人の計9グループにわけた。
グループ1から8では、6−MSITCを0.01%含むローションを1日1回、1mlずつ頭皮に塗布させ、さらにグループ2ではイソフラボンを1日50mg錠剤にて摂取、グループ3ではラズベリーケトンを1日600mg錠剤にて摂取させた。グループ4ではカプシエイトを1日2mg錠剤にて摂取、グループ5ではグルコン酸を1日100mg錠剤にて摂取させた。さらにグループ6ではクロロゲン酸を1日100mg錠剤にて摂取、グループ7ではカカオポリフェノールを1日600mg錠剤にて摂取させた。グループ8では八丁味噌を1日5000mg錠剤にて摂取させ、グループ9はコントロール群として、6−MSITCを含まないローションを同様に塗布させ、擬似錠剤を摂取させた。これを6ヶ月にわたって行った。
次に上記試験中(ローションの塗布を開始する前、3ヶ月間塗布後、および6ヶ月間塗布後)に採取しておいた抜け毛の本数を測定し、抜け毛改善効果の評価を行った。なお、上記抜け毛の測定方法は、4日間の連続洗髪を行い、後半3日間の抜け毛をメッシュの微細な不織布で採取し、その本数を計数し、行った。そして、上記評価の判定は、ローションの塗布開始前に対する各々の時期における抜け毛本数の変化から次のように表示した。
+++:抜け毛本数が30本以上減っており著しい効果を認めた。
++:抜け毛本数が20本以上減っておりかなりの効果を認めた。
+:抜け毛本数が10本以上減っておりわずかな効果を認めた。
±:抜け毛本数の減少が10本未満もしくは増加しており効果があると言えない。
この結果を、下記の表7に示す。
上記表7の結果より、6−MSITCを含有したローションを塗布したグループでは、抜け毛に対して改善効果が認められ、さらにイソフラボン等を同時に摂取させることにより顕著な改善効果が認められた。また、本テストの条件として、使用テスト中に炎症や肌トラブルなどの好ましくはない現象が現れた場合には、速やかにテストを中止すること明記していたが、本テストではこのような好ましくない反応が現れずテスト脱落者はなかった。すなわち、6−MSITCを含有したローションを塗布することで、副作用や悪影響等なく安全に、著明な抜け毛改善効果が得られることが示され、さらにイソフラボン等を同時に摂取することにより、その作用が強化されることが示された。
[Test Example 10] Test of hair growth effect on humans by applying lotion containing isothiocyanates The subject was a volunteer male (30 to 50 years old) having hair loss and thin hair trouble, and was divided into a total of 9 groups of 5 persons. .
In groups 1 to 8, 1 ml of a lotion containing 0.01% of 6-MSITC is applied to the scalp once a day, and in group 2, isoflavone is taken as a 50 mg tablet daily, and in group 3 raspberry ketone is daily It was ingested in a 600 mg tablet. In group 4, capsiate was ingested in 2 mg tablets per day, and in group 5 gluconic acid was ingested in 100 mg tablets per day. Furthermore, in group 6, chlorogenic acid was ingested in 100 mg tablets per day, and in group 7, cocoa polyphenol was ingested in 600 mg tablets per day. In group 8, Hachcho miso was ingested in a daily dose of 5000 mg tablets, and group 9 was similarly applied with a lotion containing no 6-MSITC as a control group, and ingested simulated tablets. This was done for six months.
Next, the number of hair loss collected during the above test (before the start of application of the lotion, after 3 months of application and after 6 months of application) was measured to evaluate the hair loss improving effect. In addition, the measurement method of the above-mentioned hair loss performed four days continuous hair washing, collected the hair loss of the last three days with the fine nonwoven fabric of mesh, counted the number, and was performed. And judgment of the above-mentioned evaluation was displayed as follows from change of the number of hair loss in each time to before the start of application of a lotion.
+++: The number of hair loss decreased by 30 or more, and a remarkable effect was recognized.
++: The number of hair loss decreased by 20 or more, and a considerable effect was recognized.
+: The number of hair loss decreased by 10 or more, and a slight effect was recognized.
±: The decrease in the number of hair loss is less than or increased by 10, and it can not be said to be effective.
The results are shown in Table 7 below.
From the results of Table 7 above, in the group to which the lotion containing 6-MSITC was applied, the improvement effect on hair loss was observed, and further, the remarkable improvement effect was recognized by simultaneously consuming isoflavones and the like. In addition, as a condition of this test, it was clearly stated that the test should be stopped promptly if an undesirable phenomenon such as inflammation or skin trouble appears during the use test, but such a test is not preferable in this test. There was no response and no test dropouts. That is, it has been shown that applying a lotion containing 6-MSITC can provide a significant hair loss improving effect safely without side effects or adverse effects, and by simultaneously consuming isoflavone etc. It was shown to be strengthened.
脱毛、薄毛の悩みを持っているボランティア男性(30~50歳)を対象とし、1グループ5人の計9グループにわけた。
グループ1から8では、6−MSITCを0.01%含むローションを1日1回、1mlずつ頭皮に塗布させ、さらにグループ2ではイソフラボンを1日50mg錠剤にて摂取、グループ3ではラズベリーケトンを1日600mg錠剤にて摂取させた。グループ4ではカプシエイトを1日2mg錠剤にて摂取、グループ5ではグルコン酸を1日100mg錠剤にて摂取させた。さらにグループ6ではクロロゲン酸を1日100mg錠剤にて摂取、グループ7ではカカオポリフェノールを1日600mg錠剤にて摂取させた。グループ8では八丁味噌を1日5000mg錠剤にて摂取させ、グループ9はコントロール群として、6−MSITCを含まないローションを同様に塗布させ、擬似錠剤を摂取させた。これを6ヶ月にわたって行った。
次に上記試験中(ローションの塗布を開始する前、3ヶ月間塗布後、および6ヶ月間塗布後)に採取しておいた抜け毛の本数を測定し、抜け毛改善効果の評価を行った。なお、上記抜け毛の測定方法は、4日間の連続洗髪を行い、後半3日間の抜け毛をメッシュの微細な不織布で採取し、その本数を計数し、行った。そして、上記評価の判定は、ローションの塗布開始前に対する各々の時期における抜け毛本数の変化から次のように表示した。
+++:抜け毛本数が30本以上減っており著しい効果を認めた。
++:抜け毛本数が20本以上減っておりかなりの効果を認めた。
+:抜け毛本数が10本以上減っておりわずかな効果を認めた。
±:抜け毛本数の減少が10本未満もしくは増加しており効果があると言えない。
この結果を、下記の表7に示す。
In groups 1 to 8, 1 ml of a lotion containing 0.01% of 6-MSITC is applied to the scalp once a day, and in group 2, isoflavone is taken as a 50 mg tablet daily, and in group 3 raspberry ketone is daily It was ingested in a 600 mg tablet. In group 4, capsiate was ingested in 2 mg tablets per day, and in group 5 gluconic acid was ingested in 100 mg tablets per day. Furthermore, in group 6, chlorogenic acid was ingested in 100 mg tablets per day, and in group 7, cocoa polyphenol was ingested in 600 mg tablets per day. In group 8, Hachcho miso was ingested in a daily dose of 5000 mg tablets, and group 9 was similarly applied with a lotion containing no 6-MSITC as a control group, and ingested simulated tablets. This was done for six months.
Next, the number of hair loss collected during the above test (before the start of application of the lotion, after 3 months of application and after 6 months of application) was measured to evaluate the hair loss improving effect. In addition, the measurement method of the above-mentioned hair loss performed four days continuous hair washing, collected the hair loss of the last three days with the fine nonwoven fabric of mesh, counted the number, and was performed. And judgment of the above-mentioned evaluation was displayed as follows from change of the number of hair loss in each time to before the start of application of a lotion.
+++: The number of hair loss decreased by 30 or more, and a remarkable effect was recognized.
++: The number of hair loss decreased by 20 or more, and a considerable effect was recognized.
+: The number of hair loss decreased by 10 or more, and a slight effect was recognized.
±: The decrease in the number of hair loss is less than or increased by 10, and it can not be said to be effective.
The results are shown in Table 7 below.
〔試験例11〕イソチオシアネート類の曝露による学習機能の向上作用
2群に分けた(各群5匹)に対し、4週間試験品を暴露したのち、モーリス水迷路試験を5日間行い、学習機能に対する影響を評価した。試験品は6−メチルチオヘキシルイソチオシアネート(6−MTITC)を使用し、対照群には曝露せず、通常の飼育条件とした。6−MTITCはマウスを飼育するケージ内で、市販のアロマオイル用芳香器により揮発させた。
この結果、6−MTITCを曝露させた群は、水迷路試験において開始後3日目以降プラットホームに到達するまでの時間が有意に短縮した。これは6−MSITCを摂取させた場合と全く同様の結果であった。このことから、イソチオシアネート類を曝露した場合も摂取した場合と同様の効果が得られることが確かめられた。 [Test Example 11] Improvement of learning function by exposure to isothiocyanates The test product was exposed for 4 weeks to 2 groups (5 animals in each group), then Morris water maze test was performed for 5 days, and learning function The impact on the The test product used 6-methylthiohexyl isothiocyanate (6-MTITC), was not exposed to the control group, and was under normal breeding conditions. 6-MTITC was volatilized with a commercially available aroma oil aromatic container in a cage for rearing mice.
As a result, the group exposed to 6-MTITC significantly shortened the time to reach the platform from the third day after the start in the water maze test. This was exactly the same as when 6-MSITC was ingested. From this, it was confirmed that exposure to isothiocyanates provides the same effect as ingestion.
2群に分けた(各群5匹)に対し、4週間試験品を暴露したのち、モーリス水迷路試験を5日間行い、学習機能に対する影響を評価した。試験品は6−メチルチオヘキシルイソチオシアネート(6−MTITC)を使用し、対照群には曝露せず、通常の飼育条件とした。6−MTITCはマウスを飼育するケージ内で、市販のアロマオイル用芳香器により揮発させた。
この結果、6−MTITCを曝露させた群は、水迷路試験において開始後3日目以降プラットホームに到達するまでの時間が有意に短縮した。これは6−MSITCを摂取させた場合と全く同様の結果であった。このことから、イソチオシアネート類を曝露した場合も摂取した場合と同様の効果が得られることが確かめられた。 [Test Example 11] Improvement of learning function by exposure to isothiocyanates The test product was exposed for 4 weeks to 2 groups (5 animals in each group), then Morris water maze test was performed for 5 days, and learning function The impact on the The test product used 6-methylthiohexyl isothiocyanate (6-MTITC), was not exposed to the control group, and was under normal breeding conditions. 6-MTITC was volatilized with a commercially available aroma oil aromatic container in a cage for rearing mice.
As a result, the group exposed to 6-MTITC significantly shortened the time to reach the platform from the third day after the start in the water maze test. This was exactly the same as when 6-MSITC was ingested. From this, it was confirmed that exposure to isothiocyanates provides the same effect as ingestion.
本発明の組成物は、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌のうち少なくとも1つと6−MSITCとを必須成分とするものであり、インスリン様成長因子−I誘導する働きを持つカルシトニン遺伝子関連ペプチドの産生を促進することにより、高血圧、認知症、骨粗鬆症を予防および治療する効果を持ち、抗うつ作用、学習機能の向上効果さらには頭髪等の育毛効果を有する。また、作用が穏やかで、副作用がなく、安全性が高い。このような本発明の組成物は、現代の生活において問題となる疾病の予防や治療、あるいは身体的コンプレックスの克服を図る上で、大きく役に立つことが期待される。
The composition of the present invention comprises, as essential components, at least one of isoflavone, raspberry ketone, capsiate, gluconic acid, chlorogenic acid, cocoa polyphenols, and hacho-miso and 6-MSITC, and is derived from insulin-like growth factor-I. By promoting the production of calcitonin gene-related peptide having a function to have an effect of preventing and treating hypertension, dementia, and osteoporosis, it has an antidepressant action, an improvement effect of learning function, and further a hair growth effect such as hair. In addition, it has a mild action, no side effects, and high safety. Such a composition of the present invention is expected to be greatly useful in preventing or treating diseases that cause problems in modern life, or overcoming physical complexes.
Claims (20)
- イソチオシアネート類と、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の群から選択される少なくとも一種とを組み合わせて含有し、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用またはインスリン様成長因子−1(IGF−1)分泌促進作用を呈することを特徴とするイソチオシアネート類含有組成物。 A combination of isothiocyanates and at least one member selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acid, cocoa polyphenols, and haccho miso to promote production and release of calcitonin gene related peptide (CGRP) An isothiocyanate-containing composition characterized by exhibiting an action or insulin-like growth factor-1 (IGF-1) secretion promoting action.
- 請求項1において、イソチオシアネート類が4−メチルスルフィニルブチルイソチオシアネート、5−メチルスルフィニルペンチルイソチオシアネート、6−メチルスルフィニルヘキシルイソチオシアネート、7−メチルスルフィニルヘプチルイソチオシアネート、8−メチルスルフィニルオクチルイソチオシアネート、アリルイソチオシアネート、第2級ブチルイソチオシアネート、3−ブテニルイソチオシアネート、4−ペンテニルイソチオシアネート、5−ヘキセニルイソチオシアネート、5−メチルチオペンチルイソチオシアネート、6−メチルチオヘキシルイソチオシアネート、7−メチルチオヘプチルイソチオシアネート、8−メチルチオオクチルイソチオシアネート、β−フェネチルイソチオシアネート、ベンジルイソチオシアネート、フェニルイソチオシアネート、およびフェネチルイソチオシアネートの群から選択される一種または複数種である請求項1に記載の組成物。 In Claim 1, isothiocyanates are 4-methylsulfinylbutyl isothiocyanate, 5-methylsulfinylpentyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate, 7-methylsulfinylheptyl isothiocyanate, 8-methylsulfinyloctyl isothiocyanate, allyl. Isothiocyanate, secondary butyl isothiocyanate, 3-butenyl isothiocyanate, 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 5-methyl thiopentyl isothiocyanate, 6-methyl thiohexyl isothiocyanate, 7-methyl thioheptyl isothiocyanate, 8-Methylthiooctyl isothiocyanate, β-phenethyl isothiocyanate, benzyl isothiocyanate Sulfonate composition of claim 1 which is one type or more selected from the group of phenyl isothiocyanate and phenethyl isothiocyanate.
- 請求項1において、イソチオシアネート類が化学的に合成され請求項1に記載の組成物。 The composition according to claim 1, wherein the isothiocyanates are chemically synthesized.
- 請求項1において、イソチオシアネート類がアブラナ科植物の粉砕またはすりおろし処理、溶媒による抽出処理、または乾燥処理を単独で、または組み合わせ処理することにより得られる請求項1に記載の組成物。 The composition according to claim 1, wherein the isothiocyanates are obtained by treating or crushing a cruciferous plant, extracting with a solvent, or drying, alone or in combination.
- 請求項1において、イソチオシアネート類の香りを嗅ぐことにより、インスリン様成長因子−1(IGF−1)分泌促進作用を呈する請求項1に記載の組成物。 The composition according to claim 1, wherein the composition has an insulin-like growth factor-1 (IGF-1) secretion promoting effect by sniffing the smell of isothiocyanates.
- 請求項1において、揮発したイソチオシアネート類に曝露することにより、インスリン様成長因子−1(IGF−1)分泌促進作用を呈する請求項1に記載の組成物。 The composition according to claim 1, which exhibits an insulin-like growth factor-1 (IGF-1) secretagogue action by being exposed to the volatilized isothiocyanates.
- イソチオシアネート類と、イソフラボン、ラズベリーケトン、カプシエイト、グルコン酸、クロロゲン酸、カカオポリフェノール、および八丁味噌の群から選択される少なくとも一種とを組み合わせて含有し、カルシトニン遺伝子関連ペプチド(CGRP)の産生および放出促進作用またはインスリン様成長因子−1(IGF−1)分泌促進作用を呈することを特徴とする食品、食品素材または医薬品。 A combination of isothiocyanates and at least one member selected from the group consisting of isoflavones, raspberry ketones, capsiates, gluconic acid, chlorogenic acid, cocoa polyphenols, and haccho miso to promote production and release of calcitonin gene related peptide (CGRP) Food, food material or medicine characterized by exhibiting action or insulin-like growth factor-1 (IGF-1) secretion promoting action.
- 請求項7において、インスリン様成長因子−1分泌促進作用を呈し、学習機能を向上する請求項7の食品、食品素材または医薬品。 The food, food material or medicament according to claim 7, which exhibits insulin-like growth factor-1 secretion promoting action and improves learning function.
- 請求項7において、インスリン様成長因子−1分泌促進作用を呈し、認知症およびパーキンソン病を予防および治療する請求項7の食品、食品素材または医薬品。 The food, food material or medicament according to claim 7, which exhibits insulin-like growth factor-1 secretion promoting effect according to claim 7, and prevents and treats dementia and Parkinson's disease.
- 請求項7において、インスリン様成長因子−1分泌促進作用を呈し、うつ病を予防および治療する請求項7の食品、食品素材または医薬品。 The food, food material or medicament according to claim 7, which exhibits insulin-like growth factor-1 secretion promoting effect according to claim 7, and prevents and treats depression.
- 請求項7において、インスリン様成長因子−1分泌促進作用を呈し、骨粗鬆症を治療する請求項7の食品、食品素材または医薬品。 The food, food material or medicine according to claim 7, which exhibits insulin-like growth factor-1 secretion promoting effect and treats osteoporosis.
- 請求項7において、インスリン様成長因子−1分泌促進作用を呈し、高血圧を予防および治療する請求項7の食品、食品素材または医薬品化粧品。 The food, food material or pharmaceutical cosmetic product according to claim 7, which exhibits an insulin-like growth factor-1 secretion promoting effect to prevent and treat hypertension.
- 請求項7において、インスリン様成長因子−1分泌促進作用を呈し、育毛を施す請求項7の食品、食品素材または医薬品。 The food, food material or medicament according to claim 7, which has insulin-like growth factor-1 secretion promoting action and hair growth.
- 請求項7において、イソチオシアネート類が4−メチルスルフィニルブチルイソチオシアネート、5−メチルスルフィニルペンチルイソチオシアネート、6−メチルスルフィニルヘキシルイソチオシアネート、7−メチルスルフィニルヘプチルイソチオシアネート、8−メチルスルフィニルオクチルイソチオシアネート、アリルイソチオシアネート、第2級ブチルイソチオシアネート、3−ブテニルイソチオシアネート、4−ペンテニルイソチオシアネート、5−ヘキセニルイソチオシアネート、5−メチルチオペンチルイソチオシアネート、6−メチルチオヘキシルイソチオシアネート、7−メチルチオヘプチルイソチオシアネート、8−メチルチオオクチルイソチオシアネート、β−フェネチルイソチオシアネート、ベンジルイソチオシアネート、フェニルイソチオシアネート、およびフェネチルイソチオシアネートの群から選択される一種または複数種である請求項7に記載の食品、食品素材または医薬品。 The isothiocyanates according to claim 7 are 4-methylsulfinylbutyl isothiocyanate, 5-methylsulfinylpentyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate, 7-methylsulfinylheptyl isothiocyanate, 8-methylsulfinyloctyl isothiocyanate, allyl. Isothiocyanate, secondary butyl isothiocyanate, 3-butenyl isothiocyanate, 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 5-methyl thiopentyl isothiocyanate, 6-methyl thiohexyl isothiocyanate, 7-methyl thioheptyl isothiocyanate, 8-Methylthiooctyl isothiocyanate, β-phenethyl isothiocyanate, benzyl isothiocyanate Sulfonate, phenyl isothiocyanate and food according to claim 7, which is one or more selected from the group of PEITC, food materials or medicines.
- 請求項7において、イソチオシアネート類が化学的に合成され請求項7に記載の食品、食品素材または医薬品。 The food, food material or medicine according to claim 7, wherein the isothiocyanate is chemically synthesized.
- 請求項7において、イソチオシアネート類がアブラナ科植物の粉砕またはすりおろし処理、溶媒による抽出処理、または乾燥処理を単独で、または組み合わせ処理することにより得られる請求項7に記載の食品、食品素材または医薬品。 The food, food material or food material according to claim 7, wherein the isothiocyanate is obtained by treating or grinding the cruciferous plant, extracting with a solvent, or drying treatment alone or in combination. Medicine.
- 請求項7において、イソチオシアネート類の香りを嗅ぐことにより、インスリン様成長因子−1(IGF−1)分泌促進作用を呈する請求項7に記載の食品、食品素材または医薬品。 The food, food material or medicine according to claim 7, which exhibits an insulin-like growth factor-1 (IGF-1) secretion promoting action by smelling the isothiocyanate.
- 請求項7において、揮発したイソチオシアネート類に曝露することにより、インスリン様成長因子−1(IGF−1)分泌促進作用を呈する請求項7に食品、食品素材または医薬品。 The food, food material or medicine according to claim 7, which exhibits insulin-like growth factor-1 (IGF-1) secretion promoting action by exposure to volatilized isothiocyanates.
- 請求項1の組成物または請求項7の食品、食品素材または医薬品を育毛に用い、インスリン様成長因子−1(IGF−1)分泌促進作用を呈する化粧品。 A cosmetic which exhibits the insulin-like growth factor-1 (IGF-1) secretion promoting action using the composition of claim 1 or the food, food material or medicament of claim 7 for hair growth.
- 請求項1の組成物または請求項7の食品、食品素材または医薬品を日用品に用い、イソチオシアネート類の香りを嗅ぐことにより、または揮発したイソチオシアネート類に曝露することにより、インスリン様成長因子−1(IGF−1)分泌促進作用を呈する日用品雑貨類。 An insulin-like growth factor-1 by using the composition according to claim 1 or the food, food material or medicine according to claim 7 for daily use and sniffing the smell of isothiocyanates or exposing to volatilized isothiocyanates (IGF-1) Daily necessities and general merchandise exhibiting a secretion promoting action
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009012950A JP2010001282A (en) | 2008-05-23 | 2009-01-23 | Isothiocyanate-containing composition, food, foodstuff, medicine, cosmetic, daily necessary and miscellaneous good |
JP2009-012950 | 2009-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010084661A1 true WO2010084661A1 (en) | 2010-07-29 |
Family
ID=42357637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/069512 WO2010084661A1 (en) | 2009-01-23 | 2009-11-11 | Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010084661A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015036370A (en) * | 2013-08-13 | 2015-02-23 | 晨星興産株式会社 | Hair restoration composition using sweet potato polyphenol extract |
WO2018066707A1 (en) * | 2016-10-07 | 2018-04-12 | 株式会社 Pal | Aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor |
CN107929474A (en) * | 2017-12-15 | 2018-04-20 | 苏州科技城医院 | A kind of pharmaceutical composition for treating depression |
CN108601754A (en) * | 2015-12-01 | 2018-09-28 | 宝洁公司 | Inhibit carnitine to trimethylamine(TMA)The method of conversion |
US11246844B2 (en) | 2016-06-29 | 2022-02-15 | The Procter & Gamble Company | Methods for inhibiting conversion of choline to trimethylamine (TMA) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03153614A (en) * | 1989-11-09 | 1991-07-01 | Minato Sangyo Kk | Hair tonic |
JP2003113117A (en) * | 2001-07-31 | 2003-04-18 | Daicho Kikaku:Kk | Anti-depressant medicine, anti-climacteric medicine, senile dementia medicine, alzheimer's dementia medicine |
JP2005306754A (en) * | 2004-04-19 | 2005-11-04 | Towa Corporation 株式会社 | Testosterone-increasing composition, testosterone-increasing food, testosterone-increasing skin care preparation for external use and testosterone-increasing medicine |
JP2005536449A (en) * | 2001-12-18 | 2005-12-02 | ブラシカ・ファウンデーション・ケモプロテクション・リサーチ,インコーポレイテッド | Prevention and treatment of oxidative stress disorders with glutathione and phase 2 detoxification enzymes |
JP2006016362A (en) * | 2004-07-05 | 2006-01-19 | Univ Nagoya | Agent for enhancing action of nerve growth factor |
JP2006241005A (en) * | 2005-03-01 | 2006-09-14 | Kinjirushi Kk | Skin aging-preventing agent and cosmetic |
JP2007031316A (en) * | 2005-07-25 | 2007-02-08 | Toyobo Co Ltd | Anti-ultraviolet stimulating agent using anti-mutagenicity |
JP2009126826A (en) * | 2007-11-22 | 2009-06-11 | Atsuo Sekiyama | Anti-stress agent |
JP2009155334A (en) * | 2009-01-13 | 2009-07-16 | Tsujido Chemical Corp | Medicine |
-
2009
- 2009-11-11 WO PCT/JP2009/069512 patent/WO2010084661A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03153614A (en) * | 1989-11-09 | 1991-07-01 | Minato Sangyo Kk | Hair tonic |
JP2003113117A (en) * | 2001-07-31 | 2003-04-18 | Daicho Kikaku:Kk | Anti-depressant medicine, anti-climacteric medicine, senile dementia medicine, alzheimer's dementia medicine |
JP2005536449A (en) * | 2001-12-18 | 2005-12-02 | ブラシカ・ファウンデーション・ケモプロテクション・リサーチ,インコーポレイテッド | Prevention and treatment of oxidative stress disorders with glutathione and phase 2 detoxification enzymes |
JP2005306754A (en) * | 2004-04-19 | 2005-11-04 | Towa Corporation 株式会社 | Testosterone-increasing composition, testosterone-increasing food, testosterone-increasing skin care preparation for external use and testosterone-increasing medicine |
JP2006016362A (en) * | 2004-07-05 | 2006-01-19 | Univ Nagoya | Agent for enhancing action of nerve growth factor |
JP2006241005A (en) * | 2005-03-01 | 2006-09-14 | Kinjirushi Kk | Skin aging-preventing agent and cosmetic |
JP2007031316A (en) * | 2005-07-25 | 2007-02-08 | Toyobo Co Ltd | Anti-ultraviolet stimulating agent using anti-mutagenicity |
JP2009126826A (en) * | 2007-11-22 | 2009-06-11 | Atsuo Sekiyama | Anti-stress agent |
JP2009155334A (en) * | 2009-01-13 | 2009-07-16 | Tsujido Chemical Corp | Medicine |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015036370A (en) * | 2013-08-13 | 2015-02-23 | 晨星興産株式会社 | Hair restoration composition using sweet potato polyphenol extract |
CN108601754A (en) * | 2015-12-01 | 2018-09-28 | 宝洁公司 | Inhibit carnitine to trimethylamine(TMA)The method of conversion |
CN108601753A (en) * | 2015-12-01 | 2018-09-28 | 宝洁公司 | Inhibit method of the choline to the conversion of trimethylamine (TMA) |
US10780072B2 (en) | 2015-12-01 | 2020-09-22 | The Procter & Gamble Company | Methods for inhibiting conversion of choline to trimethylamine (TMA) |
US10786479B2 (en) | 2015-12-01 | 2020-09-29 | The Procter & Gamble Company | Methods for inhibiting conversion of carnitine to trimethylamine (TMA) |
US11246844B2 (en) | 2016-06-29 | 2022-02-15 | The Procter & Gamble Company | Methods for inhibiting conversion of choline to trimethylamine (TMA) |
WO2018066707A1 (en) * | 2016-10-07 | 2018-04-12 | 株式会社 Pal | Aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor |
JPWO2018066707A1 (en) * | 2016-10-07 | 2019-09-05 | 株式会社Pal | Aging inhibitor, soft tissue calcification inhibitor, and lung tissue destruction inhibitor |
JP7068704B2 (en) | 2016-10-07 | 2022-05-17 | 株式会社Pal | Anti-aging agents, soft tissue calcification inhibitors, and lung tissue destruction inhibitors |
CN107929474A (en) * | 2017-12-15 | 2018-04-20 | 苏州科技城医院 | A kind of pharmaceutical composition for treating depression |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4693963B2 (en) | Estrogen-like agent, collagen production promoter, and fibroblast proliferating agent | |
US8828955B2 (en) | Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed | |
KR101434653B1 (en) | Novel use of flavon compounds | |
TWI361076B (en) | Composition containing extract of aframomum melegueta | |
JP2010001282A (en) | Isothiocyanate-containing composition, food, foodstuff, medicine, cosmetic, daily necessary and miscellaneous good | |
JP2004075638A (en) | Functional material having action to suppress increase of blood sugar level and suppress increase of blood pressure | |
JP2009046465A (en) | Skin cosmetic and food/drink | |
JP5403942B2 (en) | Glutathione production promoter and preventive / therapeutic agent for diseases caused by glutathione deficiency | |
WO2010084661A1 (en) | Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound | |
JP2003055244A (en) | Agent promoting hyaluronic acid production, cosmetics, food and beverage including the hyaluronic acid production-promoting agent | |
JP4672269B2 (en) | Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent, skin cosmetics and food and drink | |
JP4563659B2 (en) | Antioxidant composition, composition for preventing skin aging, anti-inflammatory composition, and composition for improving lipid metabolism | |
KR101935492B1 (en) | Composition comprising yarayara for preventing hair loss or stimulating hair growth | |
KR101914441B1 (en) | Cosmetic compositions for improving skin moisturizing comprising fucosterol | |
KR101904501B1 (en) | Cosmetic compositions for improving skin wrinkles or skin elasticity comprising fucosterol | |
US20200383890A1 (en) | Composition comprising irone as active ingredient for preventing hair loss or stimulating new hair growth | |
JP2023153108A (en) | Composition for amelioration of menopausal disorder in women containing mixed extract of hop and citrus unshiu peel as active ingredient | |
JP2019147824A (en) | Kaempferia parviflora-containing compositions | |
JP6122200B1 (en) | Anti-glycation composition | |
KR20190046685A (en) | Composition comprising nonanal for preventing hair loss or stimulating hair growth | |
JP2011032177A (en) | Inhibitor of kit cleavage | |
JP5419258B2 (en) | Cosmetics | |
KR20170136957A (en) | Composition for skin improvement comprising multiple extract | |
JP7455350B2 (en) | Damage inhibitors, cosmetics, and food and beverages caused by air pollutants | |
KR102435396B1 (en) | Composition for preventing hair loss and promoting hair growth comprising isoprostanoids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09838851 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09838851 Country of ref document: EP Kind code of ref document: A1 |